

Medications for Opioid Use Disorder

Bibliography

Part 1

1 World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment

of opioid dependence. Geneva, Switzerland: WHO Press.

2 Council of Economic Advisers. (2017). The underestimated cost of the opioid crisis. Washington, DC: Executive Office of the President of the United States.

3 American Society of Addiction Medicine. (2011). Definition of addiction. Retrieved January 9, 2018, from

4 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

5 Department of Health and Human Services, Office of the Surgeon General. (2016). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. Washington, DC: Department of Health and Human Services.

6 Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

7 National Cancer Institute. (n.d.). Remission. In NCI dictionary of cancer terms. Retrieved November 22, 2017, from

8 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

9 Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011, April 30). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*, 377(9776), 1506–1513.

10 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V.,

Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

11 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

12 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), 1–84.

13 Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède,

J. P., & Tignol, J. (2004). French field experience with buprenorphine. *American Journal on Addictions*, 13(Suppl. 1), S17–S28.

14 Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. *Drug and Alcohol Dependence*, 105(1–2), 9–15.

15 Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction*, 103(3), 462–468.

16 Schwartz, R. P., Gryczynski, J., O'Grady, K. E., Sharfstein,

J. M., Warren, G., Olsen, Y., ... Jaffe, J. H. (2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. *American Journal of Public Health*, 103(5), 917–922.

17 World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment

of opioid dependence. Geneva, Switzerland: WHO Press.

18 Brezing, C., & Bisaga, A. (2015, April 30). Opioid use disorder: Update on diagnosis and treatment. *Psychiatric Times*, 32(4) 1–4.

19 Department of Health and Human Services, Office of the Surgeon General. (2016). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. Washington, DC: Department of Health and Human Services.

20 Jones, C. M., Campopiano, M., Baldwin, G., & McCance-

Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. *American Journal of Public Health*, 105(8), e55–e63.

21 Blue Cross Blue Shield. (2017). America's opioid epidemic and its effect on the nation's commercially insured population. Washington, DC: Blue Cross Blue Shield Association.

22 Jones, C. M., Campopiano, M., Baldwin, G., & McCance-

Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. *American Journal of Public Health*, 105(8), e55–e63.

23 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), 1–84.

24 Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark,

H. W., Robillard, H., ... Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 283(10), 1303–1310.

25 Nielsen, S., Larance, B., Degenhardt, L., Gowing,

L., Kehler, C., & Lintzeris, N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. *Cochrane Database of Systematic Reviews*, 2016(5), 1–61.

26 Amato, L., Davoli, M., Perucci, C. A., Ferri, M., Faggiano, F., & Mattick, R. P. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. *Journal of Substance Abuse Treatment*, 28(4), 321–329.

27 Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. *Cochrane Database of Systematic Reviews*, 2003(3), 1–45.

28 Herget, G. (2005). Methadone and buprenorphine added to the WHO list of essential medicines. *HIV/AIDS Policy and Law Review*, 10(3), 23–24.

29 Gossop, M., Marsden, J., Stewart, D., & Kidd, T. (2003). The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. *Addiction*, 98(3), 291–303.

30 Lawrinson, P., Ali, R., Buavirat, A., Chiamwongpaet, S., Dvoryak, S., Habrat, B., ... Zhao, C. (2008). Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. *Addiction*, 103(9), 1484–1492.

31 Teesson, M., Ross, J., Darke, S., Lynskey, M., Ali, R., Ritter, A., & Cooke, R. (2006). One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). *Drug and Alcohol Dependence*, 83(2), 174–180.

32 Bruce, R. D. (2010). Methadone as HIV prevention: High volume methadone sites to decrease HIV incidence rates in resource limited settings. *International Journal on Drug Policy*, 21(2), 122–124.

33 Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin-Rittmon,

M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65(2), 146–157.

34 Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., & Ali, R. (2011). Oral substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database of Systematic Reviews*, 2011(8), 1–117.

35 MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., ... Hickman, M. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. *BMJ*, 345, e5945.

36 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

37 Metzger, D. S., & Zhang, Y. (2010). Drug treatment as HIV prevention: Expanding treatment options. *Current HIV/ AIDS Reports*, 7(4), 220–225.

38 Woody, G. E., Bruce, D., Korthuis, P. T., Chhatre, S., Poole, S., Hillhouse, M., ... Ling, W. (2014). HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. *Journal of Acquired Immune Deficiency Syndromes*, 66(3), 288–293.

39 Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65(2), 146–157.

40 Schwartz, R. P., Jaffe, J. H., O'Grady, K. E., Kinlock, T. W., Gordon, M. S., Kelly, S. M., ... Ahmed, A. (2009). Interim methadone treatment: Impact on arrests. *Drug and Alcohol Dependence*, 103(3), 148–154.

41 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V.,

Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

42 Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L.,

Kleber, H. D., Kampman, K., ... O'Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo- controlled trial. *Archives of General Psychiatry*, 63(2), 210–218.

43 Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011, April 30). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*, 377(9776), 1506–1513.

44 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

45 Lee, J. D., Nunes, E. V., Jr., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., ... Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. *Lancet*, 391(10118), 309–318.

46 Tanum, L., Solli, K. K., Latif, Z. E., Benth, J. Š., Opheim, A., Sharma-Haase, K., ... Kunøe, N. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. *JAMA Psychiatry*, 74(12), 1197–1205.

47 Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(2), 1–45.

48 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), 1–84.

49 Edelman, E. J., Chantarat, T., Caffrey, S., Chaudhry, A., O'Connor, P. G., Weiss, L., ... Fiellin, L. E. (2014). The impact of buprenorphine/naloxone treatment on HIV risk

behaviors among HIV-infected, opioid-dependent patients. *Drug and Alcohol Dependence*, 139,

79–85.

50 Sullivan, L. E., Moore, B. A., Chawarski, M. C., Pantalon,

M. V., Barry, D., O'Connor, P. G., ... Fiellin, D. A. (2008). Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. *Journal of Substance Abuse Treatment*, 35(1), 87–92.

51 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

52 Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O'Connor, P. G. (2014). Primary care- based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Internal Medicine*, 174(12), 1947–1954.

53 Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., ... Schottenfeld,

R. S. (2008). Long-term treatment with buprenorphine/ naloxone in primary care: Results at 2–5 years. *American Journal on Addictions*, 17(2), 116–120.

54 Soeffng, J. M., Martin, L. D., Fingerhood, M. I., Jasinski, D. R., & Rastegar, D. A. (2009). Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year. *Journal of Substance Abuse Treatment*, 37(4), 426–430.

55 Herget, G. (2005). Methadone and buprenorphine added to the WHO list of essential medicines. *HIV/AIDS Policy and Law Review*, 10(3), 23–24.

56 Rosenthal, R. N., Lofwall, M. R., Kim, S., Chen, M., Beebe,

K. L., Vocci, F. J., & PRO-814 Study Group. (2016). Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual

buprenorphine: A randomized clinical trial. *Journal of the American Medical Association*, 316(3), 282–290.

57 Rosenthal, R. N., Lofwall, M. R., Kim, S., Chen, M., Beebe,

K. L., & Vocci, F. J. (2016). Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual

buprenorphine: A randomized clinical trial. *JAMA*, 316(3), 282–290.

58 Barnwal, P., Das, S., Mondal, S., Ramasamy, A., Maiti, T., & Saha, A. (2017).

Probuphine® (buprenorphine implant): Promising candidate in opioid dependence.

Therapeutic Advances in Psychopharmacology, 7(3), 119–134.

59 Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., ... Taylor, R. S. (2007, March). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic

evaluation. *Health Technology Assessment*, 11(9), 1–171, iii–iv.

60 Lynch, F. L., McCarty, D., Mertens, J., Perrin, N. A., Green,

C. A., Parthasarathy, S., ... Pating, D. (2014). Costs of care for persons with opioid dependence in commercial integrated health systems. *Addiction Science and Clinical Practice*, 9, 16.

61 Baser, O., Chalk, M., Fiellin, D. A., & Gastfriend, D.

R. (2011). Cost and utilization outcomes of opioid- dependence treatments. *American Journal of Managed Care*, 17(Suppl. 8), S235–S248.

62 Schwartz, R. P., Alexandre, P. K., Kelly, S. M., O'Grady,

K. E., Gryczynski, J., & Jaffe, J. H. (2014). Interim versus standard methadone treatment: A benefit-cost analysis. *Journal of Substance Abuse Treatment*, 46(3), 306–314.

63 Cartwright, W. S. (2000). Cost-benefit analysis of drug treatment services: Review of the literature. *Journal of Mental Health Policy and Economics*, 3(1), 11–26.

64 McCollister, K. E., & French, M. T. (2003). The relative contribution of outcome domains in the total economic benefit of addiction interventions: A review of first findings. *Addiction*, 98(12), 1647–1659.

65 Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

66 Drug Enforcement Administration. (n.d.). Title 21 Code of Federal Regulations. Part 1306—Prescriptions. §1306.07 Administering or dispensing of narcotic drugs. Retrieved November 22, 2017, from

67 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

68 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), 1–84.

69 Calsyn, D. A., Malcy, J. A., & Saxon, A. J. (2006). Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. *Journal of Substance Abuse Treatment*, 30, 159–163.

70 Stimmel, B., Goldberg, J., Rotkopf, E., & Cohen, M. (1977). Ability to remain abstinent after methadone detoxification. *JAMA*, 237, 1216–1220.

71 Cushman, P. (1978). Abstinence following detoxification and methadone maintenance treatment. *American Journal of Medicine*, 65, 46–52.

72 Nosyk, B., Sun, H., Evans, E., Marsh, D. C., Anglin, M. D., Hser, Y. I., & Anis, A. H. (2012). Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study. *Addiction*, 107(9), 1621–1629.

73 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V.,

Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

74 Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark,

H. W., Robillard, H., ... Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 283(10), 1303–1310.

75 Wines, J. D., Jr., Saitz, R., Horton, N. J., Lloyd-Travaglini, C., & Samet, J. H. (2007). Overdose after detoxification: A prospective study. *Drug and Alcohol Dependence*, 89(2–3), 161–169.

76 Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. *British Medical Journal*, 326(7396), 959–960.

77 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

78 Ling, W., Amass, L., Shoptaw, S., Annon, J. J., Hillhouse, M., Babcock, D., ... Ziedonis, D. (2005). A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. *Addiction*, 100(8), 1090–1100.

79 McCusker, J., Bigelow, C., Luippold, R., Zorn, M., & Lewis,

B. F. (1995). Outcomes of a 21-day drug detoxification program: Retention, transfer to further treatment, and HIV risk reduction. *American Journal of Drug and Alcohol Abuse*, 21(1), 1–16.

80 Fiellin, D., Schottenfeld, R., Cutter, C., Moore, A., Barry, D., & O'Connor, P. (2014). Primary care based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Internal Medicine*, 174(12), 1947–1954.

81 Gruber, V., Delucchi, K., Kielstein, A., & Batki, S. (2008). A randomized trial of six-month methadone

maintenance with standard or minimal counseling versus 21-day methadone detoxification. *Drug and Alcohol Dependence*, 94, 199.

82 Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., ... Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. *Addiction*, 104(2), 256–265.

83 Smyth, B. P., Barry, J., Keenan, E., & Ducray, K. (2010). Lapse and relapse following inpatient treatment of opiate dependence. *Irish Medical Journal*, 103(6), 176–179.

84 Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011). Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. *Cochrane Database of Systematic Reviews*, 2011(9), 1–55.

85 Department of Health and Human Services, Office of the Surgeon General. (2016). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. Washington, DC: Department of Health and Human Services.

86 Saloner, B., & Karthikeyan, S. (2015). Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004–2013. *JAMA*, 314(14), 1515–1517.

87 Van Handel, M. M., Rose, C. E., Hallisey, E. J., Kolling, J. L., Zibbell, J. E., Lewis, B., ... Brooks, J. T. (2016). County- level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. *Journal of Acquired Immune Deficiency Syndromes*, 73(3), 323–331.

[Updates citations:](#)

Centers for Disease Control and Prevention. (2025, February 25). *CDC reports nearly 24% decline in U.S. drug overdose deaths.*

<https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html>

Drug Enforcement Administration. (2024, November 15). *DEA and HHS extend telemedicine flexibilities through 2025.* <https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025>

Substance Abuse and Mental Health Services Administration. (2024, January 31). *42 CFR Part 8 final rule.* <https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8>

Sunny, M. (2024, May 15). Walgreens launches own brand of opioid overdose reversal drug. *Reuters.* <https://www.reuters.com/business/healthcare-pharmaceuticals/walgreens-launches-own-brand-opioid-overdose-reversal-drug-2024-05-15/>

Part 2:

Notes

1 Shapiro, B., Coffa, D., & McCance-Katz, E. F. (2013). A primary care approach to substance misuse. *American Family Physician*, 88(2), 113–121.

2 Center for Behavioral Health Statistics and Quality. (2020). Results from the 2019 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved May 21, 2021, from

3 American Society of Addiction Medicine. (2011). Definition of addiction. Retrieved October 30, 2017, from

4 American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.

5 Department of Health and Human Services, Office of the Surgeon General. (2016). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. Washington, DC: Department of Health and Human Services.

6 Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

7 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

8 National Cancer Institute. (n.d.). Remission. In NCI dictionary of cancer terms. Retrieved November 22, 2017, from

9 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

10 McNeely, J., Wu, L. T., Subramaniam, G., Sharma, G., Cathers, L. A., Svikis, D., ... Schwartz, R. P. (2016). Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for substance use screening in primary care patients. *Annals of Internal Medicine*, 165(10), 690–699.

11 Centers for Disease Control and Prevention. (2020). Alcohol and public health: Alcohol-Related Disease Impact (ARDI). Annual average for United States 2011–2015 alcohol-attributable deaths due to excessive alcohol use. Retrieved April 28, 2021, from

12 Warner-Smith, M., Darke, S., Lynskey, M., & Hall, W. (2001). Heroin overdose: Causes and consequences. *Addiction*, 96(8), 1113–1125.

13 Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J.,

Caughey, A. B., Davidson, K. W., ... & Landefeld, C. S. (2018). Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*, 320(18), 1899–1909.

14 U.S. Preventive Services Task Force. (2018). Final Recommendation Statement: Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions. Retrieved January 11, 2020, from

15 Shapiro, B., Coffa, D., & McCance-Katz, E. F. (2013). A primary care approach to substance misuse. *American Family Physician*, 88(2), 113–121.

16 Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). *The Alcohol Use Disorders Identification Test: Guidelines for use in primary care* (2nd ed.). Geneva, Switzerland: World Health Organization.

17 Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Archives of Internal Medicine*, 158(16), 1789–1795.

18 Dawson, D. A., Smith, S. M., Saha, T. D., Rubinsky, A. D., & Grant, B. F. (2012). Comparative performance of the AUDIT-C in screening for DSM-IV and DSM-5 alcohol use disorders. *Drug and Alcohol Dependence*, 126(3), 384–388.

19 Substance Abuse and Mental Health Services Administration, & National Institute on Alcohol Abuse and Alcoholism. (2015). *Medication for the treatment of alcohol use disorder: A brief guide*. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration.

20 Smith, P. C., Schmidt, S. M., Allensworth-Davies, D., & Saitz, R. (2009). Primary care validation of a single- question alcohol screening test. *Journal of General Internal Medicine*, 24(7), 783–788.

21 Kalman, D., Morissette, S. B., & George, T. P. (2005).

Co-morbidity of smoking in patients with psychiatric and substance use disorders. *American Journal of Addictions*, 14, 106–123.

22 Department of Health and Human Services. (2014). *The health consequences of smoking—50 years of progress: A report of the Surgeon General*. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and

Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.

23 Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein,

D. U., McCormick, D., & Bor, D. H. (2000). Smoking and mental illness: A population-based prevalence study. *JAMA*, 284, 2606–2610.

24 Ong, M. O., Zhou, Q., & Sung, H. (2011). Primary care providers advising smokers to quit: Comparing

effectiveness between those with and without alcohol, drug, or mental disorders.

Nicotine and Tobacco Research, 13(12), 1193–1201.

25 U.S. Preventive Services Task Force. (2015). Tobacco smoking cessation in adults, including pregnant women: Behavioral and pharmacotherapy interventions.

26 Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*, 86(9), 1119–1127.

27 John, U., Meyer, C., Schumann, A., Hapke, U., Rumpf,

H. J., Adam, C., ... Lüdemann, J. (2004). A short form of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index in two adult population samples. *Addictive Behaviors*, 29(6), 1207–1212.

28 U.S. Preventive Services Task Force. (2020). Final Recommendation Statement—Unhealthy Drug Use: Screening. Retrieved May 3, 2021, from [g](#)

29 Shapiro, B., Coffa, D., & McCance-Katz, E. F. (2013). A primary care approach to substance misuse. *American Family Physician*, 88(2), 113–121.

30 Shapiro, B., Coffa, D., & McCance-Katz, E. F. (2013). A primary care approach to substance misuse. *American Family Physician*, 88(2), 113–121.

31 McNeely, J., Wu, L. T., Subramaniam, G., Sharma, G., Cathers, L. A., Svikis, D., ... Schwartz, R. P. (2016). Performance of the Tobacco, Alcohol, Prescription Medication,

and Other Substance Use (TAPS) Tool for substance use screening in primary care patients. *Annals of Internal Medicine*, 165(10), 690–699.

32 Smith, P. C., Schmidt, S. M., Allensworth-Davies, D., & Saitz, R. (2010). A single-question screening test for drug use in primary care. *Archives of Internal Medicine*, 170(13), 1155–1160.

33 Tiet, Q. Q., Leyva, Y. E., Moos, R. H., Frayne, S. M., Osterberg, L., & Smith, B. (2015). Screen of drug use: Diagnostic accuracy of a new brief tool for primary care. *JAMA Internal Medicine*, 175(8), 1371–1377.

34 Skinner, H. A. (1982). The Drug Abuse Screening Test. *Addictive Behaviors*, 7(4), 363–371.

35 Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). *The Alcohol Use Disorders Identification Test: Guidelines for use in primary care* (2nd ed.). Geneva, Switzerland: World Health Organization.

36 Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*, 86(9), 1119–1127.

37 McNeely, J., Strauss, S. M., Rotrosen, J., Ramautar, A., & Gourevitch, M. N. (2016). Validation of an audio computer-assisted self-interview (ACASI) version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in primary care patients. *Addiction*, 111(2), 233–244.

38 Ali, R., Meena, S., Eastwood, B., Richards, I., & Marsden, J. (2013). Ultra-rapid screening for substance-use disorders: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite). *Drug and Alcohol Dependence*, 132(1–2), 352–361.

39 Smith, P. C., Schmidt, S. M., Allensworth-Davies, D., & Saitz, R. (2010). A single-question screening test for

drug use in primary care. *Archives of Internal Medicine*, 170(13), 1155–1160.

40 Tiet, Q. Q., Leyva, Y. E., Moos, R. H., Frayne, S. M., Osterberg, L., & Smith, B. (2015). Screen of drug use: Diagnostic accuracy of a new brief tool for primary care. *JAMA Internal Medicine*, 175(8), 1371–1377.

41 Tiet, Q. Q., Leyva, Y. E., Moos, R. H., Frayne, S. M., Osterberg, L., & Smith, B. (2015). Screen of drug use: Diagnostic accuracy of a new brief tool for primary care. *JAMA Internal Medicine*, 175(8), 1371–1377.

42 National Institute on Drug Abuse. (2012). Resource guide: Screening for drug use in general medical settings. Rockville, MD: Author.

43 National Institute on Drug Abuse. (2012). Resource guide: Screening for drug use in general medical settings. Rockville, MD: Author.

44 Ali, R., Meena, S., Eastwood, B., Richards, I., & Marsden,

J. (2013). Ultra-rapid screening for substance-use disorders: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite). *Drug and Alcohol Dependence*, 132(1–2), 352–361.

45 Schwartz, R. P., McNeely, J., Wu, L. T., Sharma, G., Wahle, A., Cushing, C., ... Subramaniam, G. (2017). Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. *Journal of Substance Abuse Treatment*, 76, 69–76.

46 Wang, X., Zhang, T., & Ho, W. Z. (2011). Opioids and HIV/ HCV infection. *Journal of Neuroimmune Pharmacology*, 6(4), 477–489.

47 U.S. Preventive Services Task Force. (2019). Final Recommendation Statement on Human Immunodeficiency Virus (HIV) Infection: Screening. Retrieved June 11, 2019, from

48 Centers for Disease Control and Prevention. Testing Recommendations for Hepatitis C Virus Infection. Retrieved October 15, 2015, from

49 Merrill, J. O., Rhodes, L. A., Deyo, R. A., Marlatt, G. A., & Bradley, K. A. (2002). Mutual mistrust in the medical care of drug users: The keys to the “narc” cabinet. *Journal of General Internal Medicine*, 17(5), 327–333.

50 Shapiro, B., Coffa, D., & McCance-Katz, E. F. (2013). A primary care approach to substance misuse. *American Family Physician*, 88(2), 113–121.

51 Miller, W. R., & Rollnick, S. (2013). *Motivational interviewing: Helping people change* (3rd ed.). New York, NY: Guilford Press.

52 Center for Substance Abuse Treatment. (1999). *Brief interventions and brief therapies for substance abuse*. Treatment Improvement Protocol (TIP) Series. 34. HHS Publication No. (SMA) 12-3952. Rockville, MD: Substance Abuse and Mental Health Services Administration.

53 Miller, W. R., & Rollnick, S. (2013). *Motivational interviewing: Helping people change* (3rd ed.). New York, NY: Guilford Press.

54 Savant, J. D., Barry, D. T., Cutter, C. J., Joy, M. T., Dinh, A., Schottenfeld, R. S., & Fiellin, D. A. (2013). Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/ naloxone treatment. *Drug and Alcohol Dependence*, 127(1–3), 243–247.

55 Hassan, A. N., Howe, A. S., Samokhvalov, A. V., Le Foll, B., & George, T. P. (2017). Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. *American Journal on Addictions*, 26(6), 551–563.

56 Hall, W. D., & Strang, J. (2017). Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. *Lancet Psychiatry*, 4(4), 265–266.

57 Saitz, R. (2014). Medical and surgical complications of addiction. In R. K. Ries, D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.), *The ASAM principles of addiction medicine* (5th ed.). Philadelphia, PA: Wolters Kluwer.

58 Soper, R. G. (2014, October 6). Intimate partner violence and co-occurring substance abuse/addiction. *ASAM Magazine*. Retrieved October 16, 2017, from

59 Stone, A. L., Becker, L. G., Huber, A. M., & Catalano, R. F. (2012). Review of risk and protective factors of substance use and problem use in emerging adulthood. *Addictive Behaviors*, 37(7), 747–775.

60 American Society of Addiction Medicine. (2017). The ASAM appropriate use of drug testing in clinical addiction medicine. Rockville, MD: ASAM. Retrieved October 30, 2017, from

61 Lynch, K. (2014). San Francisco General Hospital laboratory protocol. San Francisco, CA: San Francisco General Hospital.

62 Warner, E., & Lorch, E. (2014). Laboratory diagnosis. In R. K. Ries, D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.),

Principles of addiction medicine (5th ed., pp. 332–343). Philadelphia, PA: Wolters Kluwer.

63 Milone, M. C. (2012). Laboratory testing for prescription opioids. *Journal of Medical Toxicology*, 8(4), 408–416.

64 Reisfeld, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2007). Urine drug test interpretation: What do physicians know? *Journal of Opioid Management*, 3(2), 80–86.

65 Standridge, J. B., Adams, S. M., & Zotos, A. P. (2010). Urine drug screening: A valuable office procedure. *American Family Physician*, 81(5), 635–640.

66 Standridge, J. B., Adams, S. M., & Zotos, A. P. (2010). Urine drug screening: A valuable office procedure. *American Family Physician*, 81(5), 635–640.

67 Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration.

68 American College of Obstetricians and Gynecologists. (2017, August). Opioid use and opioid use disorder

in pregnancy.

69 Ali, M. M., Dowd, N., Classen, T., Mutter, R., & Scott,

P. (2017). Prescription drugs monitoring program, nonmedical use of prescription drug and heroin use: Evidence from the National Survey of Drug Use and Health. *Addictive Behaviors*, 69, 65–77.

70 American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.

71 American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.

72 Clinical Tools. (n.d.). DSM 5 opioid use disorder checklist. Retrieved October 16, 2017, from

73 American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.

74 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Cochrane Database of Systematic Reviews, 2014(2), 1–84.

75 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

76 Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 4, CD001333.

77 Krupitsky, E., Zvartau, E., Blokhina, E., Verbitskaya, E., Wahlgren, V., Tsoy-Podosenin, M., ... Woody, G. E. (2012). Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. *Archives of General Psychiatry*, 69(9), 973–981.

78 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V.,

Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

79 McCarty, D., Braude, L., Lyman, D. R., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E. (2014). Substance abuse intensive outpatient programs: Assessing the evidence. *Psychiatric Services*, 65(6), 718–726.

80 Mee-Lee, D., Shulman, G. D., Fishman, M. J., Gastfriend,

D. R., & Miller, M. M. (Eds.). (2013). *The ASAM criteria: Treatment criteria for addictive, substance-related, and co-occurring conditions* (3rd ed.). Carson City, NV: The Change Companies.

81 Drug Enforcement Administration. (n.d.). Informational documents. Retrieved November 21, 2017, from

82 Carroll, K. M., & Weiss, R. D. (2016). The role of behavioral interventions in buprenorphine maintenance treatment: A review. *American Journal of Psychiatry*, 174(8), 738–774.

83 Fiellin, D. A., Barry, D. T., Sullivan, L. E., Cutter, C. J., Moore, B. A., O'Connor, P. G., & Schottenfeld, R. S. (2013). A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. *American Journal of Medicine*, 126(1), 74.e11–74.e77.

84 Fiellin, D. A., Barry, D. T., Sullivan, L. E., Cutter, C. J., Moore, B. A., O'Connor, P. G., & Schottenfeld, R. S. (2013). A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. *American Journal of Medicine*, 126(1), 74.e11–74.e77.

85 Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. *Addiction*, 108(10), 1788–1798.

86 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

87 Pettinati, H. M., O'Brien, C. P., & Dundon, W. D. (2013). Current status of co-occurring mood and substance use disorders: A new therapeutic target. *American Journal of Psychiatry*, 170(1), 23–30.

88 Chou, R., Korthuis, P. T., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., ... McCarty, D. (2016).

Medication-assisted treatment models of care for opioid use disorder in primary care settings. Technical Brief No. 28. Rockville, MD: Agency for Healthcare Research and Quality.

89 Department of Health and Human Services. (2021, April 28). Practice guidelines for the administration of buprenorphine for treating opioid use disorder. HHS Notice, 86 Fed. Reg. 22439. Retrieved

May 21, 2021, from

90 Department of Health and Human Services. (2021, April 28). Practice guidelines for the administration of buprenorphine for treating opioid use disorder. HHS Notice, 86 Fed. Reg. 22439. Retrieved

May 21, 2021, from

91 Substance Abuse and Mental Health Services Administration. (n.d.). Apply for a Practitioner Waiver [Webpage]. Retrieved February 14, 2020, from

92 Department of Health and Human Services. (2021, April 28). Practice guidelines for the administration of buprenorphine for treating opioid use disorder. HHS Notice, 86 Fed. Reg. 22439. Retrieved

May 21, 2021, from

- 93 Bogdanowicz, K. M., Stewart, R., Broadbent, M., Hatch, S. L., Hotopf, M., Strang, J., & Hayes, R. D. (2015). Double trouble: Psychiatric comorbidity and opioid addiction—All-cause and cause-specific mortality. *Drug and Alcohol Dependence*, 148, 85–92.
- 94 Bogdanowicz, K. M., Stewart, R., Chang, C. K., Downs, J., Khondoker, M., Shetty, H., ... Hayes, R. D. (2016). Identifying mortality risks in patients with opioid use disorder using brief screening assessment: Secondary mental health clinical records analysis. *Drug and Alcohol Dependence*, 164, 82–88.
- 95 Department of Health and Human Services. (2016). The opioid epidemic: By the numbers. Washington, DC: Department of Health and Human Services.
- 96 Substance Abuse and Mental Health Services Administration. (2016). SAMHSA opioid overdose prevention toolkit. HHS Publication No. (SMA) 16-4742. Rockville, MD: Author.
- 97 Centers for Disease Control and Prevention, National Center for Health Statistics. (2020). Multiple Cause of Death 2018-2019 on CDC WONDER Online Database, released in 2020. Retrieved April 29, 2021, from
- 98 Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2019). Drug and opioid-involved overdose deaths— United States, 2013–2017. *Morbidity and Mortality Weekly Report*, 67(5152), 1419.
- 99 Centers for Disease Control and Prevention, National Center for Health Statistics. (2020). Multiple Cause of Death 2018–2019 on CDC WONDER Online Database, released in 2020. Retrieved April 29, 2021, from
- 100Centers for Disease Control and Prevention. (2016). Increases in drug and opioid-involved overdose deaths— United States, 2010–2015. *Morbidity and Mortality Weekly Report*, 65(50–51), 1445–1452.
- 101Albert, S., Brason, F. W., II, Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in rural North Carolina. *Pain Medicine*, 12(Suppl. 2), S77–S85.

102Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., ... Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. *British Medical Journal*, 346, f174.

103Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Archives of Internal Medicine*, 158(16), 1789–1795.

104Skinner, H. A. (1982). The Drug Abuse Screening Test. *Addictive Behavior*, 7(4), 363–371.

105Yudko, E., Lozhkina, O., & Fouts, A. (2007). A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. *Journal of Substance Abuse Treatment*, 32, 189–198.

106American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed., p. 541). Arlington, VA: American Psychiatric Publishing.

107McNeely, J., Wu, L. T., Subramaniam, G., Sharma, G., Cathers, L. A., Svikis, D., ... Schwartz, R. P. (2016).

Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for substance use screening in primary care patients. *Annals of Internal Medicine*, 165(10), 690–699.

Updated Citations in Part 2

Drug Enforcement Administration. (2024, November 15). *DEA and HHS extend telemedicine flexibilities through 2025*. <https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025>

Lei, F., Lofwall, M. R., McAninch, J., Adatorwovor, R., Slade, E., Freeman, P. R., Moga, D. C., Dasgupta, N., Walsh, S. L., Vickers-Smith, R., & Slavova, S. (2024). Higher first

30-day dose of buprenorphine for opioid use disorder treatment is associated with decreased mortality. *Journal of Addiction Medicine*, 18(3), 319–326.
https://journals.lww.com/journaladdictionmedicine/fulltext/2024/05000/higher_first_30_day_dose_of_buprenorphine_for.15.aspx

Substance Abuse and Mental Health Services Administration. (2024a, January 31). 42 CFR Part 8 final rule. <https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8>

Substance Abuse and Mental Health Services Administration. (2024b). 42 CFR Part 8 final rule—FAQs. <https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8/faqs>

U.S. Department of Health and Human Services, Office for Civil Rights. (2024, February 8). *Fact sheet: 42 CFR Part 2 final rule*. <https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html>

U.S. Department of Health and Human Services; Substance Abuse and Mental Health Services Administration; Office for Civil Rights. (2024, February 16). *Confidentiality of substance use disorder (SUD) patient records; final rule*. *Federal Register*.
<https://www.federalregister.gov/documents/2024/02/16/2024-02544/confidentiality-of-substance-use-disorder-sud-patient-records>

Part 3

Notes

1 Department of Health and Human Services. (2016). The opioid epidemic: By the numbers. Washington, DC: Author.

2 Center for Behavioral Health Statistics and Quality. (2020). Results from the 2019 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved April 28, 2021, from

3 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

4 Weiss, A. J., Elixhauser, A., Barrett, M. L., Steiner, C. A., Bailey, M. K., & O'Malley, L. (2017, January). Opioid- related inpatient stays and emergency department visits by

state, 2009–2014. HCUP Statistical Brief No. 219. Rockville, MD: Agency for Healthcare Research and Quality.

5 Agency for Healthcare Research and Quality. (2020). Rate of opioid-related ED visits per 100,000 population. Retrieved April 28, 2021, from

6 American Society of Addiction Medicine. (2011). Definition of addiction. Chevy Chase, MD: American Society of Addiction Medicine. Retrieved January 5, 2018, from

7 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

8 Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

9 Substance Abuse and Mental Health Services Administration. (2016). Pocket guide: Medication-assisted treatment of opioid use disorder. HHS Publication No. (SMA) 16-4892PG. Rockville, MD: Substance Abuse and Mental Health Services Administration.

10 Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

11 Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010). Pharmacotherapy in the treatment of addiction: Methadone. *Journal of Addictive Diseases*, 29(2), 200–216.

12 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

13 World Health Organization. (2015). 19th WHO model list of essential medicines. Geneva, Switzerland: Author.

14 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Cochrane Database of Systematic Reviews, 2014(2), 1–84.

15 Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark,

H. W., Robillard, H., ... Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 283(10), 1303–1310.

16 Nielsen, S., Larance, B., Degenhardt, L., Gowing,

L., Kehler, C., & Lintzeris, N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. *Cochrane Database of Systematic Reviews*, 2016(5), 1–61.

17 Stoller, K. B., Stephens, M. A. C., & Schorr, A. (2016). Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. Retrieved October 16, 2017, from

18 Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L.,

Kleber, H. D., Kampman, K., ... O'Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. *Archives of General Psychiatry*, 63(2), 210–218.

19 Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*, 377(9776), 1506–1513.

20 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V.,

Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

21 American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.

22 Lee, J. D., McDonald, R., Grossman, E., McNeely, J., Laska, E., Rotrosen, J., & Gourevitch, M. N. (2015). Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial. *Addiction*, 110(6), 1008–1014.

23 Leslie, D. L., Milchak, W., Gastfriend, D. R., Herschman, P. L., Bixler, E. O., Velott, D. L., & Meyer, R. E. (2015). Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up. *American Journal on Addictions*, 24(3), 265–270.

24 Sullivan, M. A., Garawi, F., Bisaga, A., Comer, S. D., Carpenter, K., Raby, W. N., ... Nunes, E. V. (2007). Management of relapse in naltrexone maintenance for heroin dependence. *Drug and Alcohol Dependence*, 91(2–3), 289–292.

25 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), 1–84.

26 World Health Organization. (2015). 19th WHO model list of essential medicines. Geneva, Switzerland: Author.

27 Jaffe, J. H., & O’Keeffe, C. (2003). From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. *Drug and Alcohol Dependence*, 70(2 Suppl.), S3–S11.

28 Department of Health and Human Services. (2021, April 28). Practice guidelines for the administration of buprenorphine for treating opioid use disorder. HHS Notice, 86 Fed. Reg. 22439. Retrieved

May 21, 2021, from [services%29](#)

29 Ling, W., Casadonte, P., Bigelow, G., Kampman, K. M., Patkar, A., Bailey, G. L., ... Beebe, K. L. (2010). Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 304(14), 1576–1583.

30 Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

31 Kinlock, T. W., Gordon, M. S., Schwartz, R. P., Fitzgerald, T. T., & O'Grady, K. E. (2009). A randomized clinical trial of methadone maintenance for prisoners: Results at twelve-months post-release. *Journal of Substance Abuse Treatment*, 37(3), 277–285.

32 McKenzie, M., Zaller, N., Dickman, S. L., Green, T. C., Parikh, A., Friedmann, P. D., & Rich, J. D. (2012). A randomized trial of methadone initiation prior to release from incarceration. *Substance Abuse*, 33(1), 19–29.

33 Gordon, M. S., Kinlock, T. W., Schwartz, R. P., O'Grady, K. E., Fitzgerald, T. T., & Vocci, F. J. (2017). A randomized trial of buprenorphine for prisoners: Findings at 12-months post-release. *Drug and Alcohol Dependence*, 172, 34–42.

34 Vocci, F. J., Schwartz, R. P., Wilson, M. E., Gordon, M. S., Kinlock, T. W., Fitzgerald, T. T., O'Grady, K. E., & Jaffe, J. H. (2015). Buprenorphine dose induction in non- opioid-tolerant pre-release prisoners. *Drug and Alcohol Dependence*, 156, 133–138.

35 Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration.

36 Binder, T., & Vavrínková, B. (2008). Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. *Neuro Endocrinology Letters*, 29(1), 80–86.

37 Fajemirokun-Odukeyi, O., Sinha, C., Tutty, S., Paireudeau, P., Armstrong, D., Phillips, T., & Lindow, S. W. (2006). Pregnancy outcome in women who use opiates. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 126(2), 170–175.

38 Stimmel, B., & Adamsons, K. (1976). Narcotic dependency in pregnancy. Methadone maintenance compared to use of street drugs. *JAMA*, 235, 1121–1124.

39 Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration.

40 Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

41 American College of Obstetricians and Gynecologists Committee Opinion. (2017, August). Opioid use and opioid use disorder in pregnancy. Number 711.

42 Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration.

43 American College of Obstetricians and Gynecologists Committee Opinion. (2017, August). Opioid use and opioid use disorder in pregnancy. Number 711.

44 American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.

45 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2014(2). CD002207.

46 Lee, J. D., Nunes, E. V., Jr., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., ... Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. *Lancet*, 391(10118), 309–318.

47 Tanum, L., Solli, K. K., Latif, Z. E., Benth, J. Š., Opheim, A., Sharma-Haase, K., ... Kunøe, N. (2017). The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. *JAMA Psychiatry*, 74(12), 1197–1205.

48 Department of Veterans Affairs & Department of Defense. (2015). VA/DoD clinical practice guideline for the management of substance use disorders. Retrieved October 16, 2017, from

49 Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., ... Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 283(10), 1303–1310.

50 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

51 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

52 Gowing, L., Ali, R., White, J. M., & Mbewe, D. (2017). Buprenorphine for managing opioid withdrawal. *Cochrane Database of Systematic Reviews*, 2017(2). CD002025.

53 Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. *Drug and Alcohol Dependence*, 105(1–2), 9–15.

54 Hser, Y. I., Huang, D., Saxon, A. J., Woody, G., Moskowitz,

A. L., Matthews, A. G., & Ling, W. (2017). Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone. *Journal of Addiction Medicine*, 11(1), 63–69.

55 Novick, D. M., Salsitz, E. A., Joseph, H., & Kreek, M.

J. (2015). Methadone medical maintenance: An early 21st-century perspective. *Journal of Addictive Diseases*, 34(2–3), 226–237.

56 Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., ... Schottenfeld,

R. S. (2008). Long-term treatment with buprenorphine/ naloxone in primary care: Results at 2-5 years. *American Journal on Addictions*, 17(2), 116–120.

57 Krupitsky, E., Nunes, E. V., Ling, W., Gastfriend, D. R., Memisoglu, A., & Silverman, B. L. (2013). Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. *Addiction*, 108(9), 162–1637.

58 Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., & Butelman, E. R. (2012). Opiate addiction and cocaine addiction: Underlying molecular neurobiology and genetics. *Journal of Clinical Investigation*, 122(10), 3387–3393.

59 Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. *New England Journal of Medicine*, 374(4), 363–371.

60 Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., ... Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. *Addiction*, 104(2), 256–265.

61 Senay, E. C., Dorus, W., & Thornton, W. (1977). Withdrawal from methadone maintenance: Rate of withdrawal and expectation. *Archives of General Psychiatry*, 34(3), 361–367.

62 Sigmon, S. C., Dunn, K. E., Saulsgiver, K., Patrick, M. E., Badger, G. J., Heil, S. H., ... Higgins, S. T. (2013). A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. *JAMA Psychiatry*, 70(12), 1347–1354.

63 Department of Veterans Affairs & Department of Defense. (2015). VA/DoD clinical practice guideline for the management of substance use disorders. Retrieved October 16, 2017, from

64 Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin-Rittmon,

M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65(2), 146–157.

65 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

66 Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R., & Ferri M. (2013). Methadone at tapered doses for the management of opioid withdrawal. *Cochrane Database of Systematic Reviews*, 2013(2). CD003409.

67 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

68 Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., & Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. *Addiction*, 104(2), 256–265.

69 Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011). Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. *Cochrane Database of Systematic Reviews*, 2011(9). CD005031.

70 Nunes, E. V., Gordon, M., Friedmann, P. D., Fishman, M. J., Lee, J. D., Chen, D. T., ... O'Brien, C. P. (2018).

Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. *Journal of Substance Abuse Treatment*, 85, 49–55.

71 Satoh, M., & Minami, M. (1995). Molecular pharmacology of the opioid receptors. *Pharmacology*

& Therapeutics, 68(3), 343–364.

72 Akbarali, H. I., Inkisar, A., & Dewey, W. L. (2014). Site and mechanism of morphine tolerance in the gastrointestinal tract. *Neurogastroenterology and Motility*, 26(10), 1361–1367.

73 Bodnar, R. J. (2017). Endogenous opiates and behavior, 2015. *Peptides*, 88, 126–188.

74 Johnson, R. E., Strain, E. C., & Amass, L. (2003). Buprenorphine: How to use it right. *Drug and Alcohol Dependence*, 70(Suppl.), S59–S77.

75 Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(2). CD001333.

76 Substance Abuse and Mental Health Services Administration. (2016). Sublingual and transmucosal buprenorphine for opioid use disorder: Review and update. Advisory, Vol. 15, Issue 1. Rockville, MD: Substance Abuse and Mental Health Services Administration.

77 Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010). Pharmacotherapy in the treatment of addiction: Methadone. *Journal of Addictive Diseases*, 29(2), 200–216.

78 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

79 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.

80 Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. *Drug and Alcohol Dependence*, 105(1–2), 9–15.

81 Metzger, D. S., Woody, G. E., McLellan, A. T., O'Brien, C. P., Druley, P., Navaline, H., ... Abrutyn, E. J. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. *Journal of Acquired Immune Deficiency Syndromes*, 6(9), 1049–1056.

82 Ball, J. C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment. New York, NY: Springer Verlag.

83 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2). CD002207.

84 Walsh, S. L., & Strain, E. C. (2006). Pharmacology of methadone. In E. C. Strain & M. L. Stitzer (Eds.), *The treatment of opioid dependence* (pp. 59–76). Baltimore, MD: John Hopkins University Press.

85 Mallinckrodt Pharmaceuticals. (2017). Label: Methadose - methadone hydrochloride concentrate; Methadose sugar- free- methadone hydrochloride concentrate. Retrieved January 9, 2018, from

86 Walsh, S. L., & Strain, E. C. (2006). Pharmacology of methadone. In E. C. Strain & M. L. Stitzer (Eds.), *The treatment of opioid dependence* (pp. 59–76). Baltimore, MD: John Hopkins University Press.

87 Payte, J. T., & Zweben, J. E. (1998). Opioid maintenance therapies. In A. W. Graham, T. K. Schultz, & B. B. Wilford (Eds.), *Principles of addiction medicine* (pp. 557–570). Chevy Chase, MD: American Society of Addiction Medicine.

88 Eap, C. B., Buclin, T., & Baumann, P. (2002). Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. *Clinical Pharmacokinetics*, 41(14), 1153–1193.

89 Mallinckrodt Pharmaceuticals. (2017). Label: Methadose - methadone hydrochloride concentrate; Methadose sugar- free- methadone hydrochloride concentrate. Retrieved January 9, 2018, from

90 Oda, Y., & Kharasch, E. D. (2001). Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): Potential contribution of intestinal metabolism to presystemic clearance and bioactivation. *Journal of Pharmacology and Experimental Therapeutics*, 298(3), 1021–1032.

91 Eap, C. B., Buclin, T., & Baumann, P. (2002). Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. *Clinical Pharmacokinetics*, 41(14), 1153–1193.

92 Eap, C. B., Buclin, T., & Baumann, P. (2002). Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. *Clinical Pharmacokinetics*, 41(14), 1153–1193.

93 American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.

94 Federal opioid treatment standards, 42 CFR § 8.12
(2015).

95 Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., ... Zeltzer, L. (2014).

Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *Journal of Pain*, 15(4), 321–337.

96 Baxter, L. E., Sr., Campbell, A., Deshields, M., Levounis, P., Martin, J. A., McNicholas, L., ... Wilford, B. B. (2013). Safe methadone induction and stabilization: Report of an expert panel. *Journal of Addiction Medicine*, 7(6), 377–386.

97 Food and Drug Administration. (2016, March). FDA Drug Safety Communications, FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressant: Careful medication management can reduce risks. Retrieved January 3, 2018, from

98 Lintzeris, N., & Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. *American Journal on Addictions*, 19(1), 59–72.

99 Bart, G., Wyman, Z., Wang, Q., Hodges, J. S., Karim, R., & Bart, B. A. (2017). Methadone and the QTc interval: Paucity of clinically significant factors in a retrospective cohort. *Journal of Addiction Medicine*, 11(6), 489–493.

100 Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., ... Zeltzer, L. (2014).

Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *Journal of Pain*, 15(4), 321–337.

101 Bednar, M. M., Harrigan, E. P., & Ruskin, J. N. (2002). Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. *American Journal of Cardiology*, 89(11), 1316–1319.

102 Al-Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., & Califf, R. M. (2003). What clinicians should know about the QT interval. *JAMA*, 289(16), 2120–2127.

103Martin, J. A., Campbell, A., Killip, T., Kotz, M., Krantz,

M. J., Kreek, M. J., ... Wilford, B. B. (2011). QT interval screening in methadone maintenance treatment: Report of a SAMHSA expert panel. *Journal of Addictive Diseases*, 30(4), 283–306.

104Bazett, H. C. (1997). An analysis of the time-relations of electrocardiograms. *Annals of Noninvasive Electrocardiology*, 2(2), 177–194.

105Martin, J. A., Campbell, A., Killip, T., Kotz, M., Krantz,

M. J., Kreek, M. J., ... Wilford, B. B. (2011). QT interval screening in methadone maintenance treatment: Report of a SAMHSA expert panel. *Journal of Addictive Diseases*, 30(4), 283–306.

106Mallinckrodt Pharmaceuticals. (2015). Methadose™ dispersible tablets, 40 mg (Methadone hydrochloride tablets for oral suspension USP), CII - Generic products. Retrieved October 16, 2017, from

107Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., ... Zeltzer, L. (2014).

Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *Journal of Pain*, 15(4), 321–337.

108Krantz, M. J., Martin, J., Stimmel, B., Mehta, D., & Haigney, M. C. (2009). QTc interval screening in

methadone treatment. *Annals of Internal Medicine*, 150(6), 387–395.

109Bart, G., Wyman, Z., Wang, Q., Hodges, J. S., Karim, R., & Bart, B. A. (2017). Methadone and the QTc interval: Paucity of clinically significant factors in a retrospective cohort. *Journal of Addiction Medicine*, 11(6), 489–493.

110Pani, P. P., Trogu, E., Maremmanni, I., & Pacini, M. (2013). QTc interval screening for cardiac risk in methadone treatment of opioid dependence. *Cochrane Database of Systematic Reviews*, 2013(6). CD008939.

111Martin, J. A., Campbell, A., Killip, T., Kotz, M., Krantz,

M. J., Kreek, M. J., ... Wilford, B. B. (2011). QT interval screening in methadone maintenance treatment: Report of a SAMHSA expert panel. *Journal of Addictive Diseases*, 30(4), 283–306.

112Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., ... Zeltzer, L. (2014).

Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *Journal of Pain*, 15(4), 321–337.

113Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., ... Zeltzer, L. (2014).

Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *Journal of Pain*, 15(4), 321–337.

114Jones, H. E., Dengler, E., Garrison, A., O'Grady, K. E., Seashore, C., Horton, E., ... Thorp, J. (2014).

Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. *Drug and Alcohol Dependence*, 134, 414–417.

115Cleary, B. J., Reynolds, K., Eogan, M., O'Connell, M. P., Fahey, T., Gallagher, P. J., ... Murphy, D. J. (2014). Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. *Addiction*, 108(4), 762–770.

116Kaltenbach, K., Holbrook, A. M., Coyle, M. G., Heil,

S. H., Salisbury, A. L., Stine, S. M., ... Jones, H. E. (2012). Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. *Addiction*, 107(Suppl. 1), 45–52.

117Food and Drug Administration. (2016, March). FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.

118McCance-Katz, E. F., Sullivan, L. E., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. *American Journal on Addictions*, 19(1), 4–16.

119Martin, J., Zweben, J. E., & Payte, J. T. (2014). Opioid maintenance treatment. In R. K. Ries, D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.), *The ASAM principles of addiction medicine* (5th ed., pp. 759–777). Philadelphia, PA: Wolters Kluwer Health.

120Saxon, A. J., & Miotto, K. (2011). Methadone maintenance. In P. Ruiz & E. Strain (Eds.), *Lowinson*

and Ruiz's substance abuse: A comprehensive textbook (5th ed., pp. 419–436). Philadelphia, PA: Wolters Kluwer Health.

121McCance-Katz, E. F., Rainey, P. M., Jatlow, P., & Friedland,

G. (1998). Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 18(5), 435–443.

122World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: WHO Press.

123American College of Obstetricians and Gynecologists Committee Opinion. (2017, August). Opioid use and opioid use disorder in pregnancy. Number 711.

124Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

125U.S. Preventive Services Task Force. (2019). Final Recommendation Statement on Human Immunodeficiency Virus (HIV) Infection: Screening. Retrieved June 11, 2019, from

126Centers for Disease Control and Prevention. Testing Recommendations for Hepatitis C Virus Infection.

October 15, 2015. Retrieved from

127Centers for Disease Control and Prevention. (2016). Viral hepatitis. Retrieved December 1, 2017, from

128Baxter, L. E., Sr., Campbell, A., Deshields, M., Levounis, P., Martin, J. A., McNicholas, L., ... Wilford, B. B. (2013). Safe methadone induction and stabilization: Report of an expert panel. *Journal of Addiction Medicine*, 7(6), 377–386.

129McCance-Katz, E. F., Sullivan, L. E., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. *American Journal on Addictions*, 19(1), 4–16.

130Baxter, L. E., Sr., Campbell, A., Deshields, M., Levounis, P., Martin, J. A., McNicholas, L., ... Wilford, B. B. (2013). Safe methadone induction and stabilization: Report of an expert panel. *Journal of Addiction Medicine*, 7(6), 377–386.

131Jones, H. E. (2004). Practical considerations for the clinical use of buprenorphine. *Science and Practice Perspectives*, 2(2), 4–20.

132Vocci, F. J., Schwartz, R. P., Wilson, M. E., Gordon, M. S., Kinlock, T. W., Fitzgerald, T. T., ... Jaffe, J. H. (2015). Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. *Drug and Alcohol Dependence*, 156, 133–138.

133Kinlock, T. W., Gordon, M. S., Schwartz, R. P., & O'Grady, K. E. (2008). A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. *Criminal Justice and Behavior*, 35(1), 34–47.

134Martin, J., Zweben, J. E., & Payte, J. T. (2014). Opioid maintenance treatment. In R. K. Ries, D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.), *The ASAM principles of addiction medicine* (5th ed., pp. 759–777). Philadelphia, PA: Wolters Kluwer.

135Baxter, L. E., Sr., Campbell, A., Deshields, M., Levounis, P., Martin, J. A., McNicholas, L., ... Wilford, B. B. (2013). Safe methadone induction and stabilization: Report of an expert panel. *Journal of Addiction Medicine*, 7(6), 377–386.

136Center for Substance Abuse Treatment. (1993). *State methadone treatment guidelines*. HHS Publication No. (SMA) 93-1991. Rockville, MD: Substance Abuse and Mental Health Services Administration.

137Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., ... Zeltzer, L. (2014).

Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *Journal of Pain*, 15(4), 321–337.

138Gowing, L., Ali, R., Dunlop, A., Farrell, M., & Lintzeris, N. (2014). *National guidelines for medication-assisted treatment of opioid dependence*. Retrieved January 4, 2018, from [guidelines-for-medication-assisted-treatment-of-opioid-dependence.pdf](#)

139Leavitt, S. B., Shinderman, M., Maxwell, S., Eap, C. B., & Paris, P. (2000). When “enough” is not enough: New perspectives on optimal methadone maintenance dose. *Mount Sinai Journal of Medicine*, 67(5–6), 404–411.

140Payte, J. T. (2002). Opioid agonist treatment of addiction. Slide presentation at ASAM Review Course in Addiction Medicine.

141Leavitt, S. B. (2003). The methadone dose debate continues. *Addiction Treatment Forum*, 12(1), 1,3.

142Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

143Benmebarek, M., Devaud, C., Gex-Fabry, M., Powell Golay, K., Brogli, C., Baumann, P., ... Eap, C. B. (2004). Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. *Clinical Pharmacology and Therapeutics*, 76(1), 55–63.

144Drozdzick, J., III, Berghella, V., Hill, M., & Kaltenbach,

K. (2002). Methadone trough levels in pregnancy. *American Journal of Obstetrics and Gynecology*, 187(5), 1184–1188.

145Leavitt, S. B., Shinderman, M., Maxwell, S., Eap, C. B., & Paris, P. (2000). When “enough” is not enough: New perspectives on optimal methadone maintenance dose. *Mount Sinai Journal of Medicine*, 67(5–6), 404–411.

146Hallinan, R., Ray, J., Byrne, A., Agho, K., & Attia, J. (2006). Therapeutic thresholds in methadone maintenance treatment: A receiver operating characteristic analysis.

Drug and Alcohol Dependence, 81, 129–136.

147Stine, S. M., & Kosten, T. R. (2014). Pharmacologic interventions for opioid dependence. In R. K. Ries,

D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.), *The ASAM principles of addiction medicine* (5th ed., pp. 745–758). Philadelphia, PA: Wolters Kluwer.

148Drozdzick, J., III, Berghella, V., Hill, M., & Kaltenbach,

K. (2002). Methadone trough levels in pregnancy. *American Journal of Obstetrics and Gynecology*, 187(5), 1184–1188.

149Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

150 Food and Drug Administration. (2008). Methadose™ oral concentrate. Retrieved October 16, 2017, from

151 Department of Veterans Affairs & Department of Defense. (2015). VA/DoD clinical practice guideline for the management of substance use disorders. Retrieved October 16, 2017, from

152 Stitzer, M. L., Iguchi, M. Y., & Felch, L. J. (1992). Contingent take-home incentive: Effects on drug use of methadone maintenance patients. *Journal of Consulting and Clinical Psychology*, 60(6), 927–934.

153 Gwin Mitchell, S., Kelly, S. M., Brown, B. S., Schacht Reisinger, H., Peterson, J. A., Ruhf, A., ... Schwartz, R. P. (2009). Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. *American Journal on Addictions*, 118(5), 346–355.

154 Vlahov, D., O'Driscoll, P., Mehta, S. H., Ompad, D. C., Gern, R., Galai, N., & Kirk, G. D. (2007). Risk factors for methadone outside treatment programs: Implications for HIV treatment among injection drug users. *Addiction*, 102(5), 771–777.

155 Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-

assisted treatment for opiate dependence: A systematic review. *Journal of Addictive Diseases*, 35(1), 22–35.

156 Woody, G. E., Kane, V., Lewis, K., & Thompson, R. (2007). Premature deaths after discharge from methadone maintenance: A replication. *Journal of Addiction Medicine*, 1(4), 180–185.

157 Sordo, L., Barrio, G., Bravo, M. J., Indave, I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017).

Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. *BMJ*, 357, j1550.

158Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction*, 103(3), 462–468.

159Schwartz, R. P., Highfeld, D. A., Jaffe, J. H., Brady, J. V., Butler, C. B., Rouse, C. O., ... Battjes, R. J. (2006). A randomized controlled trial of interim methadone maintenance. *Archives of General Psychiatry*, 63(1), 102–109.

160Yancovitz, S. R., Des Jarlais, D. C., Peyser, N. P., Drew, E., Friedmann, P., Trigg, H. L., & Robinson, J. W. (1991). A randomized trial of an interim methadone maintenance clinic. *American Journal of Public Health*, 81(9), 1185–1191.

161Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

162Martin, W. R., Jasinski, D. R., & Mansky, P. A. (1973). Naltrexone, an antagonist for the treatment of heroin dependence: Effects in man. *Archives of General Psychiatry*, 28(6), 784–791.

163Sullivan, M. A., Garawi, F., Bisaga, A., Comer, S. D., Carpenter, K., Raby, W. N., ... Nunes, E. V. (2007). Management of relapse in naltrexone maintenance for heroin dependence. *Drug and Alcohol Dependence*, 91(2–3), 289–292.

164American Society of Addiction Medicine. (2015). National practice guideline for the use of medications in the treatment of addiction involving opioid use. Retrieved December 1, 2017, from

165Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(2), 1–45.
doi:10.1002/14651858.CD001333.pub3

166Alkermes. (2015). Vivitrol. Retrieved May 21, 2017, from <http://medlibrary.org/lib/rx/meds/vivitrol/page/6>

167Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*, 377(9776), 1506–1513.

168Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016).

Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

169Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011, April 30). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*, 377(9776), 1506–1513.

170Lee, J. D., Nunes, E. V., Jr., Novo, P., Bachrach, K., Bailey,

G. L., Bhatt, S., ... Rotrosen J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. *Lancet*, 391(10118), 309–318.

171Tanum, L., Solli, K. K., Latif, Z. E., Benth, J. Š., Opheim, A., Sharma-Haase, K., ... Kunøe, N. (2017). The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. *JAMA Psychiatry*, 74(12), 1197–1205.

172Meyer, M. C., Straughn, A. B., Lo, M. W., Schary, W. L., & Whitney, C. C. (1984). Bioequivalence, dose-

proportionality, and pharmacokinetics of naltrexone after oral administration. *Journal of Clinical Psychiatry*, 45(9 Pt 2), 15–19.

173Alkermes. (2015). Vivitrol (naltrexone for extended release injectable suspension) 380 mg/vial. Retrieved January 9, 2018, from

174Alkermes. (2015). Vivitrol (naltrexone for extended release injectable suspension) 380 mg/vial. Retrieved January 9, 2018, from

175Meyer, M. C., Straughn, A. B., Lo, M. W., Schary, W. L., & Whitney, C. C. (1984). Bioequivalence, dose-

proportionality, and pharmacokinetics of naltrexone after oral administration. *Journal of Clinical Psychiatry*, 45(9, Pt. 2), 15–19.

176Bigelow, G. E., Preston, K. L., Schmittner, J., Dong, Q., & Gastfriend, D. R. (2012). Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose-effects and time-course. *Drug and Alcohol Dependence*, 123(1–3), 57–65.

177Tetrault, J. M., Tate, J. P., McGinnis, K. A., Goulet, J. L., Sullivan, L. E., Bryant, K., ... Fiellin, D. A. (2012). Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. *Alcoholism: Clinical and Experimental Research*, 36(2), 318–324.

178Comer, S. D., Mannelli, P., Alam, D., Douaihy, A., Nangia, N., Akerman, S. C., ... Sullivan, M. A. (2020). Transition of patients with opioid use disorder from buprenorphine to extended-release naltrexone: A randomized clinical trial assessing two transition regimens. *American Journal on Addictions*, 29(4), 313–322.

179Bisaga, A., Mannelli, P., Yu, M., Nangia, N., Graham, C. E., Tompkins, D. A., ... Sullivan, M. A. (2018). Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. *Drug and Alcohol Dependence*, 187, 171–178.

180Comer, S. D., Mannelli, P., Alam, D., Douaihy, A., Nangia, N., Akerman, S. C., ... Sullivan, M. A. (2020). Transition of patients with opioid use disorder from buprenorphine to extended-release naltrexone: A randomized clinical trial assessing two transition regimens. *American Journal on Addictions*, 29(4), 313–322.

181Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., ... Fischer, G. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. *New England Journal of Medicine*, 363(24), 2320–2331.

182Mozurkewich, E. L., & Rayburn, W. F. (2014). Buprenorphine and methadone for opioid addiction during pregnancy. *Obstetrics and Gynecology Clinics of North America*, 41(2), 241–253.

183Alkermes. (2015). Vivitrol. Retrieved October 16, 2017, from

184Bisaga, A., Mannelli, P., Yu, M., Nangia, N., Graham, C. E., Tompkins, D. A., ... Sullivan, M. A. (2018). Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. *Drug and Alcohol Dependence*, 187, 171–178.

185Comer, S. D., Mannelli, P., Alam, D., Douaihy, A., Nangia, N., Akerman, S. C., ... Sullivan, M. A. (2020). Transition of patients with opioid use disorder from buprenorphine to extended-release naltrexone: A randomized clinical trial assessing two transition regimens. *American Journal on Addictions*, 29(4), 313–322.

186Sullivan, M., Bisaga, A., Pavlicova, M., Choi, C. J., Mishlen, K., Carpenter, K. M., ... Nunes, E. V. (2017). Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. *American Journal of Psychiatry*, 174(5), 459–467.

187Tetrault, J. M., Tate, J. P., McGinnis, K. A., Goulet, J. L., Sullivan, L. E., Bryant, K., ... Fiellin, D. A. (2012). Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. *Alcoholism: Clinical and Experimental Research*, 36(2), 318–324.

188Crowley, T. J., Wagner, J. E., Zerbe, G., & Macdonald,

M. (1985). Naltrexone-induced dysphoria in former opioid addicts. *American Journal of Psychiatry*, 142(9), 1081–1084.

189Miotto, K., McCann, M., Basch, J., Rawson, R., & Ling,

W. (2002). Naltrexone and dysphoria: Fact or myth?

American Journal on Addictions, 11(2), 151–160.

190Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

191National Library of Medicine. (2014). NALTREXONE HYDROCHLORIDE - naltrexone hydrochloride tablet, flm coated DAILY MED. Retrieved October 16, 2017, from

192Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

193Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

194Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

195U.S. Preventive Services Task Force. (2019). Final Recommendation Statement on Human Immunodeficiency Virus (HIV) Infection: Screening. Retrieved January 11, 2020, from

196Centers for Disease Control and Prevention. Testing Recommendations for Hepatitis C Virus Infection.

October 15, 2015. Retrieved January 11, 2020, from

197Centers for Disease Control and Prevention. (2016). Viral hepatitis. Retrieved October 16, 2017, from

198Nunes, E. V., Krupitsky, E., Ling, W., Zummo, J., Memisoglu, A., Silverman, B. L., & Gastfriend, D. R. (2015). Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond? *Journal of Addiction Medicine*, 9(3), 238–243.

199Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

200Sigmon, S. C., Bisaga, A., Nunes, E. V., O'Connor, P. G., Kosten, T., & Woody, G. (2012). Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. *American Journal of Drug and Alcohol Abuse*, 38(3), 187–199.

201Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

202Comer, S. D., Mannelli, P., Alam, D., Douaihy, A., Nangia, N., Akerman, S. C., ... Sullivan, M. A. (2020). Transition of patients with opioid use disorder from buprenorphine to extended-release naltrexone: A randomized clinical trial assessing two transition regimens. *American Journal on Addictions*, 29(4), 313–322.

203Sullivan, M. A., Bisaga, A., Mariani, J. J., Glass, A., Levin,

F. R., Comer, S. D., & Nunes, E. V. (2013). Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade? *Drug and Alcohol Dependence*, 133(1), 80–85.

204Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

205Kosten, T. R., Morgan, C., & Kleber, H. D. (1992). Phase II clinical trials of buprenorphine: Detoxification and induction onto naltrexone. NIDA Research Monograph, 121, 101–119.

206Bisaga, A., Sullivan, M. A., Glass, A., Mishlen, K., Pavlicova, M., Haney, M., ... Nunes, E. V. (2015). The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug and Alcohol Dependence, 154, 38–45.

207Sigmon, S. C., Bisaga, A., Nunes, E. V., O'Connor, P. G., Kosten, T., & Woody, G. (2012). Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. American Journal of Drug and Alcohol Abuse, 38(3), 187–199.

208Sullivan, M., Bisaga, A., Pavlicova, M., Choi, C. J., Mishlen, K., Carpenter, K. M., ... Nunes, E. V. (2017). Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. American Journal of Psychiatry, 174(5), 459–467.

209Sullivan, M., Bisaga, A., Pavlicova, M., Choi, C. J., Mishlen, K., Carpenter, K. M., ... Nunes, E. V. (2017). Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. American Journal of Psychiatry, 174(5), 459–467.

210Bisaga, A. (2015). Implementing antagonist-based relapse prevention treatment for buprenorphine-treated individuals. Providence, RI: Providers' Clinical Support System for Medication-Assisted Treatment.

211Shearer, J., Wodak, A. D., & Dolan, K. A. (2007). Evaluation of a prison-based naltrexone program. International Journal of Prisoner Health, 3(3), 214–224.

212Adi, Y., Juarez-Garcia, A., Wang, D., Jowett, S., Frew, E., Day, E., ... Burls, A. (2007). Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation.

Health Technology Assessment, 11(6), iii–iv, 1–85.

213Department of Veterans Affairs & Department of Defense. (2015). VA/DoD clinical practice guideline for the management of substance use disorders. Retrieved October 16, 2017, from

214Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(2), 1–45.

215Ling, W., & Wesson, D. R. (1984). Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. *Journal of Clinical Psychiatry*, 45(9 Pt. 2), 46–48.

216Washton, A. M., Gold, M. S., & Pottash, A. C. (1984). Successful use of naltrexone in addicted physicians and business executives. *Advances in Alcohol and Substance Abuse*, 4(2), 89–96.

217Sullivan, M. A., Rothenberg, J. L., Vosburg, S. K., Church, S. H., Feldman, S. J., Epstein, E. M., ... Nunes, E. V. (2006). Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a Stage I trial. *American Journal on Addictions*, 15(2), 150–159.

218Sullivan, M. A., Garawi, F., Bisaga, A., Comer, S. D., Carpenter, K., Raby, W. N., ... Nunes, E. V. (2007). Management of relapse in naltrexone maintenance for heroin dependence. *Drug and Alcohol Dependence*, 91(2–3), 289–292.

219Sullivan, M. A., Garawi, F., Bisaga, A., Comer, S. D., Carpenter, K., Raby, W. N., ... Nunes, E. V. (2007). Management of relapse in naltrexone maintenance for heroin dependence. *Drug and Alcohol Dependence*, 91(2–3), 289–292.

220American Society of Addiction Medicine. (2017). Sample treatment agreement. Retrieved October 19, 2017, from

221Alkermes. (2013). Patient counseling tool: VIVITROL (naltrexone for extended-release injectable suspension. Retrieved January 9, 2018, from

222Alkermes. (2015). Key techniques to reduce severe injection site reactions: VIVITROL (naltrexone for extended release injectable suspension) intramuscular injection. Retrieved January 9, 2018, from

223Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2014(2), 1–84.

224Caldiero, R. M., Parran, T. J., Adelman, C. L., & Piche, B. (2006). Inpatient initiation of buprenorphine maintenance vs. detoxification: Can retention of opioid-dependent patients in outpatient counseling be improved? American Journal on Addictions, 15(1), 1–7.

225Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry, 68(12), 1238–1246.

226Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., ... Schottenfeld,

R. S. (2008). Long-term treatment with buprenorphine/ naloxone in primary care: Results at 2–5 years. American Journal on Addictions, 17(2), 116–120.

227Edelman, E. J., Chantarat, T., Caffrey, S., Chaudhry, A., O'Connor, P. G., Weiss, L., ... Fiellin, L. E. (2014). The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug and Alcohol Dependence, 139, 79–85.

228Sullivan, L. E., Moore, B. A., Chawarski, M. C., Pantalon,

M. V., Barry, D., O'Connor, P. G., ... Fiellin, D. A. (2008). Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal of Substance Abuse Treatment, 35(1), 87–92.

229Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède,

J. P., & Tignol, J. (2004). French field experience with buprenorphine. *American Journal on Addictions*, 13(Suppl. 1), S17–S28.

230Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. *Drug and Alcohol Dependence*, 105(1–2), 9–15.

231Herget, G. (2005). Methadone and buprenorphine added to the WHO list of essential medicines. *HIV/AIDS Policy and Law Review*, 10(3), 23–24.

232Department of Veterans Affairs & Department of Defense. (2015). VA/DoD clinical practice guideline for the management of substance use disorders. Retrieved October 16, 2017, from

233Orexo US. (2016). Zubsolv (buprenorphine and naloxone) sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

234BioDelivery Sciences International. (2018). Bunavail (buprenorphine and naloxone buccal film): Highlights of prescribing information. Retrieved April 28, 2021, from

235BioDelivery Sciences International. (2018). Bunavail (buprenorphine and naloxone buccal film): Highlights of prescribing information. Retrieved April 28, 2021, from

236Food and Drug Administration. (n.d.). Drugs@FDA: FDA approved drug products. Retrieved October 16, 2017, from

237Roxane Laboratories. (2015). Buprenorphine and naloxone sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

238Food and Drug Administration. (n.d.). Drugs@FDA: FDA approved drug products. Retrieved October 16, 2017, from

239Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

240Food and Drug Administration. (n.d.). Drugs@FDA: FDA approved drug products. Retrieved October 16, 2017, from

- 241Indivior. (2015). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from
- 242Orexo US. (2015). Zubsolv (buprenorphine and naloxone) sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from
- 243Food and Drug Administration. (n.d.). Drugs@FDA: FDA approved drug products. Retrieved October 16, 2017, from
- 244Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from
- 245Indivior. (2015). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from
- 246Substance Abuse and Mental Health Services Administration. (2016). Sublingual and transmucosal buprenorphine for opioid use disorder: Review and update. Advisory, Vol. 15, Issue 1. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- 247Substance Abuse and Mental Health Services Administration. (2016). Sublingual and transmucosal buprenorphine for opioid use disorder: Review and update. Advisory, Vol. 15, Issue 1. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- 248Amass, L., Kamien, J. B., & Mikulich, S. K. (2001). Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. *Drug and Alcohol Dependence*, 61(2), 173–181.
- 249Schottenfeld, R. S., Pakes, J., O'Connor, P., Chawarski, M., Oliveto, A., & Kosten, T. R. (2000). Thrice-weekly versus daily buprenorphine maintenance. *Biological Psychiatry*, 47(12), 1072–1079.
- 250Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. *Clinical Pharmacology and Therapeutics*, 55(5), 569–580.

251Elkader, A., & Sproule, B. (2005). Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. *Clinical Pharmacokinetics*, 44(7), 661–680.

252Kuhlman, J. J., Jr., Levine, B., Johnson, R. E., Fudala,

P. J., & Cone, E. J. (1998). Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. *Addiction*, 93(4), 549–559.

253Indivior. (2016). Label: Suboxone – buprenorphine hydrochloride, naloxone hydrochloride flm, soluble. Retrieved January 9, 2018, from

254Marsch, L. A., Bickel, W. K., Badger, G. J., & Jacobs, E. A. (2005). Buprenorphine treatment for opioid dependence: The relative efficacy of daily, twice and thrice weekly dosing. *Drug & Alcohol Dependence*, 77(2), 195–204.

255Jones, J. D., Sullivan, M. A., Vosburg, S. K., Manubay,

J. M., Mogali, S., Metz, V., & Comer, S. D. (2015). Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. *Addiction Biology*, 20(4), 784–798.

256Walsh, S. L., Nuzzo, P. A., Babalonis, S., Casselton, V., & Lofwall, M. R. (2016). Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. *Drug and Alcohol Dependence*, 162, 190–198.

257Indivior. (2017). Sublocade (buprenorphine extended- release) injection: Full prescribing information. Retrieved December 18, 2017, from

258Elkader, A., & Sproule, B. (2005). Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. *Clinical Pharmacokinetics*, 44(7), 661–680.

259Zhang, W., Ramamoorthy, Y., Tyndale, R. F., & Sellers,

E. M. (2003). Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. *Drug Metabolism and Disposition: The Biological Fate of Chemicals*, 31(6), 768–772.

260McCance-Katz, E. F., Sullivan, L. E., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. *American Journal on Addictions*, 19(1), 4–16.

261Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. *Journal of Addiction Medicine*, 8(5), 315–326.

262Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. *Journal of Addiction Medicine*, 8(5), 315–326.

263Selden, T., Ahlner, J., Druid, H., & Kronstrand, R. (2012). Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. *Forensic Science International*, 220(1–3), 284–290.

264Hakkinen, M., Launiainen, T., Vuori, E., & Ojanpera, I. (2012). Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. *European Journal of Clinical Pharmacology*, 68(3), 301–309.

265Indivior. (2015). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from

266Toce, M. S., Burns, M. M., & O'Donnell, K. A. (2017). Clinical effects of unintentional pediatric buprenorphine exposures: Experience at a single tertiary care center. *Clinical Toxicology (Philadelphia, Pa.)*, 55(1), 12–17.

267Saxon, A. J., Ling, W., Hillhouse, M., Thomas, C., Hasson, A., Ang, A., ... Jacobs, P. (2013). Buprenorphine/ naloxone and methadone effects on laboratory indices of liver health: A randomized trial. *Drug and Alcohol Dependence*, 128(1–2), 71–76.

268Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

269Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

270Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. *Clinical Pharmacokinetics*, 54(8), 837–849.

271Durand, F., & Valla, D. (2008). Assessment of prognosis of cirrhosis. *Seminars in Liver Disease*, 28(1), 110–122.

272Durand, F., & Valla, D. (2008). Assessment of prognosis of cirrhosis. *Seminars in Liver Disease*, 28(1), 110–122.

273Indivior. (2015). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from

274Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. *Clinical Pharmacokinetics*, 54(8), 837–849.

275Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

276Indivior. (2015). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from [prescribing-information.pdf](#)

277Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. *Clinical Pharmacokinetics*, 54(8), 837–849.

278Durand, F., & Valla, D. (2008). Assessment of prognosis of cirrhosis. *Seminars in Liver Disease*, 28(1), 110–122.

279Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. *Clinical Pharmacokinetics*, 54(8), 837–849.

280Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

281Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. *Clinical Pharmacokinetics*, 54(8), 837–849.

282Substance Abuse and Mental Health Services Administration. (2016). Sublingual and transmucosal buprenorphine for opioid use disorder: Review and update. Advisory, Vol. 15, Issue 1. Rockville, MD: Substance Abuse and Mental Health Services Administration.

283Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. *Journal of Addiction Medicine*, 8(5), 315–326.

284Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. *Journal of Addiction Medicine*, 8(5), 315–326.

285Indivior. (2016). Suboxone (buprenorphine and naloxone) sublingual film: Full prescribing information. Retrieved October 16, 2017, from

286Indivior. (2016). Suboxone (buprenorphine and naloxone) sublingual film: Full prescribing information. Retrieved October 16, 2017, from

287Strain, E. C., & Lofwall, M. R. (Eds.). (2008). Buprenorphine. *The American Psychiatric Publishing textbook of substance abuse treatment* (4th ed.). Arlington, VA: American Psychiatric Publishing.

288Walsh, S. L., June, H. L., Schuh, K. J., Preston, K.

L., Bigelow, G. E., & Stitzer, M. L. (1995). Effects of buprenorphine and methadone in methadone-maintained subjects. *Psychopharmacology*, 119(3), 268–276.

289Strain, E. C., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1995). Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone. *Journal of Pharmacology and Experimental Therapeutics*, 272(2), 628–638.

290Rosado, J., Walsh, S. L., Bigelow, G. E., & Strain, E. C. (2007). Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. *Drug and Alcohol Dependence*, 90(2–3), 261–269.

291Walsh, S. L., June, H. L., Schuh, K. J., Preston, K.

L., Bigelow, G. E., & Stitzer, M. L. (1995). Effects of buprenorphine and methadone in methadone-maintained subjects. *Psychopharmacology*, 119(3), 268–276.

292Jones, H. E., Dengler, E., Garrison, A., O'Grady, K. E., Seashore, C., Horton, E., ... Thorp, J. (2014).

Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. *Drug and Alcohol Dependence*, 134, 414–417.

293Cleary, B. J., Reynolds, K., Eogan, M., O'Connell, M. P., Fahey, T., Gallagher, P. J., ... Murphy, D. J. (2014). Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. *Addiction*, 108(4), 762–770.

294Kaltenbach, K., Holbrook, A. M., Coyle, M. G., Heil, S. H., Salisbury, A. L. Stine, S. M., ... Jones, H. E. (2012). Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. *Addiction*, 107(Suppl. 1), 45–52.

295McCance-Katz, E. F., Sullivan, L. E., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. *American Journal on Addictions*, 19(1), 4–16.

296Center for Substance Abuse Treatment. (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. HHS Publication No. (SMA) 04-3939.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

297Indivior. (2016). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from

298McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., DiFrancesco, R., Friedland, G., ... Rainey, P. M. (2007).

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. *Drug and Alcohol Dependence*, 91(2–3), 269–278.

299Bruce, R. D., & Altice, F. L. (2006). Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. *AIDS*, 20(5), 783–784.

300Vergara-Rodriguez, P., Tozzi, M. J., Botsko, M., Nandi, V., Altice, F., Egan, J. E., ... Fiellin, D. A. (2011).

Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid- dependent patients. *Journal of Acquired Immune Deficiency Syndromes*, 56(Suppl. 1), S62–S67.

301McCance-Katz, E. F., Moody, D. E., Prathikanti, S., Friedland, G., & Rainey, P. M. (2011). Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. *Drug and Alcohol Dependence*, 118(2–3), 326–334.

302Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

303McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., DiFrancesco, R., Friedland, G., ... Rainey, P. M. (2007).

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. *Drug and Alcohol Dependence*, 91(2–3), 269–278.

304McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., DiFrancesco, R., Friedland, G., ... Rainey, P. M. (2007).

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. *Drug and Alcohol Dependence*, 91(2–3), 269–278.

305 Bruce, R. D., Moody, D. E., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2013). A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice. *Expert Review of Clinical Pharmacology*, 6(3), 249–269.

306 Roxane Laboratories. (2015). Buprenorphine HCl sublingual tablets: Full prescribing information. Retrieved October 16, 2017, from

307 Bruce, R. D., Moody, D. E., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2013). A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice. *Expert Review of Clinical Pharmacology*, 6(3), 249–269.

308 Gruber, V. A., Rainey, P. M., Moody, D. E., Morse, G. D., Ma, Q., Prathikanti, S., ... McCance-Katz, E. F. (2012). Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. *Clinical Infectious Diseases*, 54(3), 414–423.

309 Bruce, R. D., Moody, D. E., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2013). A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice. *Expert Review of Clinical Pharmacology*, 6(3), 249–269.

310 McCance-Katz, E. F., Moody, D. E., Morse, G. D.,

Friedland, G., Pade, P., Baker, J., ... Rainey, P. M. (2006). Interactions between buprenorphine and antiretrovirals.

I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. *Clinical Infectious Diseases*, 43(Suppl. 4), S224–S234.

311 McCance-Katz, E. F., Moody, D. E., Morse, G. D.,

Friedland, G., Pade, P., Baker, J., ... Rainey, P. M. (2006). Interactions between buprenorphine and antiretrovirals.

The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. *Clinical Infectious Diseases*, 43(Suppl. 4), S224–S234.

312 Bruce, R. D., Winkle, P., Custodio, J., Yin, X., Rhee, M., Andrews, J., ... Ramanathan, S. (2012, September).

Pharmacokinetics of cobicistat-boosted elvitegravir administered in combination with methadone or buprenorphine/naloxone. Paper presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.

313 McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., & Rainey, P. M. (2010). Lack of clinically significant drug interactions between nevirapine and buprenorphine. *American Journal on Addictions*, 19(1), 30–37.

314 McCance-Katz, E. F., Moody, D. E., Smith, P. F., Morse, G. D., Friedland, G., Pade, P., ... Rainey, P. (2006). Interactions between buprenorphine and antiretrovirals.

The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. *Clinical Infectious Diseases*, 43(Suppl. 4), S235–S246.

315 Bruce, R. D., Altice, F. L., Moody, D. E., Lin, S. N., Fang, W. B., Sabo, J. P., ... Friedland, G. H. (2009). Pharmacokinetic interactions between buprenorphine/ naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. *Drug and Alcohol Dependence*, 105(3), 234–239.

316 Substance Abuse and Mental Health Services Administration. (2016). Sublingual and transmucosal buprenorphine for opioid use disorder: Review and update. Advisory, Vol. 15, Issue 1. Rockville, MD: Substance Abuse and Mental Health Services Administration.

317 Isenberg, D., Wong, S. C., & Curtis, J. A. (2008). Serotonin syndrome triggered by a single dose of Suboxone. *American Journal of Emergency Medicine*, 26(7), 840.e3–840.e5.

318Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

319Soyka, M. (2013). Buprenorphine use in pregnant opioid users: A critical review. *CNS Drugs*, 27(8), 653–662.

320Saxon, A. J., Ling, W., Hillhouse, M., Thomas, C., Hasson, A., Ang, A., ... Jacobs, P. (2013). Buprenorphine/ naloxone and methadone effects on laboratory indices of liver health: A randomized trial. *Drug and Alcohol Dependence*, 128(1–2), 71–76.

321Vergara-Rodriguez, P., Tozzi, M. J., Botsko, M., Nandi, V., Altice, F., Egan, J. E., ... Fiellin, D. A. (2011).

Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid- dependent patients. *Journal of Acquired Immune Deficiency Syndromes*, 56(Suppl. 1), S62–S67.

322U.S. Preventive Services Task Force. (2019). Final Recommendation Statement on Human Immunodeficiency Virus (HIV) Infection: Screening. Retrieved January 11, 2020, from

323Centers for Disease Control and Prevention. Testing Recommendations for Hepatitis C Virus Infection.

October 15, 2015. Retrieved January 11, 2020, from

324Centers for Disease Control and Prevention. (2016). Viral hepatitis. Retrieved October 16, 2017, from

325Lofwall, M. R., & Havens, J. R. (2012). Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. *Drug and Alcohol Dependence*, 126(3), 379–383.

326Bazazi, A. R., Yokell, M., Fu, J. J., Rich, J. D., & Zaller, N.

D. (2011). Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. *Journal of Addiction Medicine*, 5(3), 175–180.

327Moratti, E., Kashanpour, H., Lombardelli, T., & Maisto,

M. (2010). Intravenous misuse of buprenorphine: Characteristics and extent among patients undergoing drug maintenance therapy. *Clinical Drug Investigation*, 30(Suppl. 1), 3–11.

328Braeburn Pharmaceuticals. (2016). Probuphine (buprenorphine) implant: Full prescribing information. Retrieved October 16, 2017, from

329Braeburn Pharmaceuticals. (2016). Probuphine (buprenorphine) implant: Full prescribing information. Retrieved October 16, 2017, from

330Center for Substance Abuse Treatment. (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. HHS Publication No. (SMA) 04-3939.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

331Walley, A. Y., Alperen, J. K., Cheng, D. M., Botticelli, M., Castro-Donlan, C., Samet, J. H., & Alford, D. P. (2008). Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. *Journal of General Internal Medicine*, 23(9), 1393–1398.

332Gunderson, E. W., Wang, X. Q., Fiellin, D. A., Bryan, B., & Levin, F. R. (2010). Unobserved versus observed office buprenorphine/naloxone induction: A pilot randomized clinical trial. *Addictive Behaviors*, 35(5), 537–540.

333Lee, J. D., Vocci, F., & Fiellin, D. A. (2014). Unobserved “home” induction onto buprenorphine. *Journal of Addiction Medicine*, 8(5), 299–308.

334American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.

335Providers Clinical Support System for Medication Assisted Treatment. (2013, November). PCSS Guidance. Retrieved December 18, 2017, from

336Tompkins, D. A., & Strain, E. C. (2011). Buprenorphine in the treatment of opioid dependence. In P. Ruiz & E.

C. Strain (Eds.), *Substance abuse. A comprehensive textbook* (5th ed., pp. 437–446). Philadelphia, PA: Wolters Kluwer.

337Indivior. (2016). Suboxone (buprenorphine and naloxone) sublingual flm: Full prescribing information. Retrieved October 16, 2017, from [prescribing-information.pdf](#)

338Strain, E. C. (2006). Clinical use of buprenorphine. In E.

C. Strain & M. L. Stitzer (Eds.) *The treatment of opioid dependence* (pp. 230–252). Baltimore, MD: Johns Hopkins University Press.

339Rich, J. D., McKenzie, M., Dickman, S., Bratberg, J., Lee, J. D., & Schwartz, R. P. (2011). An adverse reaction to buprenorphine/naloxone induction in prison: A case report. *Addictive Disorders and Their Treatment*, 10(4), 199–200.

340Vocci, F. J., Schwartz, R. P., Wilson, M. E., Gordon, M. S., Kinlock, T. W., Fitzgerald, T. T., ... Jaffe, J. H. (2015). Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. *Drug and Alcohol Dependence*, 156, 133–138.

341Tompkins, D. A., & Strain, E. C. (2011). Buprenorphine in the treatment of opioid dependence. In P. Ruiz & E.

C. Strain (Eds.), *Substance abuse: A comprehensive textbook* (5th ed., pp. 437–446). Philadelphia, PA: Wolters Kluwer.

342Rosado, J., Walsh, S. L., Bigelow, G. E., & Strain, E. C. (2007). Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. *Drug and Alcohol Dependence*, 90(2–3), 261–269.

343Zubieta, J., Greenwald, M. K., Lombardi, U., Woods, J. H., Kilbourn, M. R., Jewett, D. M., ... Johanson, C. E. (2000). Buprenorphine-induced changes in mu-opioid

receptor availability in male heroin-dependent volunteers: A preliminary study. *Neuropsychopharmacology*, 23(3), 326–334.

344Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M. ... Ling, W. (2014). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. *Addiction*, 109(1), 79–87.

345American College of Obstetricians and Gynecologists Committee Opinion. (2017, August). Opioid use and opioid use disorder in pregnancy. Number 711.

346Debelak, K., Morrone, W. R., O'Grady, K. E., & Jones, H.

E. (2013). Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. *American Journal on Addictions*, 22, 252–254.

347Wiegand, S. L., Stringer, E. M., Stuebe, A. M., Jones, H., Seashore, C., & Thorp, J. (2015). Buprenorphine and naloxone compared with methadone treatment in pregnancy. *Obstetrics & Gynecology*, 125, 363–368.

348American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.

349Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

350Chavoustie, S., Frost, M., Snyder, O., Owen, J., Darwish, M., Dammerman, R., & Sanjurjo, V. (2017). Buprenorphine implants in medical treatment of opioid addiction. *Expert Review of Clinical Pharmacology*, 10(8), 799–807.

351Hser, Y. I., Huang, D., Saxon, A. J., Woody, G., Moskowitz,

A. L., Matthews, A. G., & Ling, W. (2017). Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone. *Journal of Addiction Medicine*, 11(1), 63–69.

352Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., ... Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. *Addiction*, 104(2), 256–265.

353Substance Abuse and Mental Health Services Administration. (2016). Sublingual and transmucosal buprenorphine for opioid use disorder: Review and update. Advisory, Vol. 15, Issue 1. Rockville, MD: Substance Abuse and Mental Health Services Administration.

354American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.

355Henry-Edwards, S., Gowing, L., White, J., Ali, R., Bell, J., Brough, R., ... Quigley, A. (2003). Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioid dependence. Publication approval number: 3263 (JN 7616).

356World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: WHO Press.

357Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., ... Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. *Addiction*, 104(2), 256–265.

358Food and Drug Administration. (2017, May). Appropriate use checklist: Buprenorphine-containing transmucosal products for opioid dependence. Silver Spring, MD: Author.

359American Society of Addiction Medicine. (2017). Sample treatment agreement. Retrieved October 19, 2017, from

360Food and Drug Administration. (2017). FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. Retrieved December 18, 2017, from

361Lintzeris, N., & Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. *American Journal on Addictions*, 19(1), 59–72.

362Lintzeris, N., & Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. *American Journal on Addictions*, 19(1), 59–72.

363Liebschutz, J. M., Crooks, D., Herman, D., Anderson, B., Tsui, J., Meshesha, L. Z., ... Stein, M. (2014).

Buprenorphine treatment for hospitalized, opioid- dependent patients: A randomized clinical trial. *JAMA Internal Medicine*, 174(8), 1369–1376.

364Weiss, L., Netherland, J., Egan, J. E., Flanigan, T. P., Fiellin, D. A., Finkelstein, R., & Altice, F. L. (2011). Integration of buprenorphine/naloxone treatment into HIV clinical care: Lessons from the BHIVES collaborative. *Journal of Acquired Immune Deficiency Syndromes*, 56(Suppl. 1), S68–S75.

365Weiss, R. D., Potter, J. S., Griffn, M. L., Provost, S. E., Fitzmaurice, G. M., McDermott, K. A., ... Carroll, K. M. (2015). Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. *Drug and Alcohol Dependence*, 150, 112–119.

366Substance Abuse and Mental Health Services Administration. (2005). Substance abuse treatment for persons with cooccurring disorders. Treatment

Improvement Protocol (TIP) Series 42. HHS Publication No. (SMA) 133992. Rockville, MD: Substance Abuse and Mental Health Services Administration.

367Center for Substance Abuse Treatment. (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. HHS Publication No. (SMA) 04-3939.

Rockville, MD: Substance Abuse and Mental Health Services Administration.

368Drug Addiction Treatment Act of 2000, H. R. 2634 (1999–2000).

369Vujanovic, A. A., Bonn-Miller, M. O., & Petry, N. M. (2016). Co-occurring posttraumatic stress and substance use: Emerging research on correlates, mechanisms, and treatments—Introduction to the special issue. *Psychology of Addictive Behaviors*, 30(7), 713–719.

370Stitzer, M. L., & Vandrey, R. (2008). Contingency management: Utility in the treatment of drug abuse disorders. *Clinical Pharmacology and Therapeutics*, 83(4), 644–647.

371Donovan, D. M., Ingalsbe, M. H., Benbow, J., & Daley,

D. C. (2013). 12-step interventions and mutual support programs for substance use disorders: An overview. *Social Work in Public Health*, 28(3–4), 313–332.

372Donovan, D. M., Ingalsbe, M. H., Benbow, J., & Daley,

D. C. (2013). 12-step interventions and mutual support programs for substance use disorders: An overview. *Social Work in Public Health*, 28(3–4), 313–332.

373McLellan, A. T., & White, W. (2012). Opioid maintenance and recovery-oriented systems of care: It is time to integrate (p. 2). London, England: National Treatment Agency for Substance Misuse.

374American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.

375Substance Abuse and Mental Health Services Administration. (2012). Clinical drug testing in primary care. Technical Assistance Publication (TAP) Series

32. HHS Publication No. (SMA) 12-4668. Rockville, MD: Substance Abuse and Mental Health Services Administration.

376Jarvis, M., Williams, J., Hurford, M., Lindsay, D., Lincoln, P., Giles, L., ... Safarian, T. (2017). Appropriate use of drug testing in clinical addiction medicine. *Journal of Addiction Medicine*, 11(3), 163–173.

377Stoller, K. B., Stephens, M. A. C., & Schorr, A. (2016). Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. Retrieved May 21, 2017, from

378Rich, J. D., McKenzie, M., Larney, S., Wong, J. B., Tran, L., Clarke, J., ... Zaller, N. (2015, July 25). Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomised, open-label trial. *Lancet*, 386(9991), 350–359.

379Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. *Journal of Addiction Medicine*, 8(5), 315–326.

380Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C.-E., Astemborski, J., Kirk, G. D., ... Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. *Addictive Behaviors*, 38(12), 2868–2873.

381Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C.-E., Astemborski, J., Kirk, G. D., ... Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. *Addictive Behaviors*, 38(12), 2868–2873.

382Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). Factors contributing to the rise of buprenorphine misuse: 2008-2013. *Drug and Alcohol Dependence*, 142, 98–104.

383Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. *Journal of Addiction Medicine*, 8(5), 315–326.

384United States National Library of Medicine. (2017, October). Buprenorphine sublingual and buccal (opioid dependence). Retrieved December 18, 2017, from

385American Society of Addiction Medicine. (2016). Sample office-based opioid use disorder policy and procedure manual. Retrieved October 19, 2017, from [org/docs/default-source/advocacy/sample](#)

386Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

387Medication Assisted Treatment for Opioid Use Disorders. HHS Final Rule, Fed. Reg. 81 44711 (July 8, 2016) (to be codified at 42 CFR pt. 8).

388Physical security controls for practitioners, 21 CFR § 1301.75 (2016).

389American Society of Addiction Medicine. (2016). Sample office-based opioid use disorder policy and procedure manual. Retrieved October 19, 2017, from [-diversion-policy.pdf?sfvrsn=0](#)

390Records for manufacturers, distributors, dispensers, researchers, importers, exporters, registrants that reverse distribute, and collectors, 21 CFR § 1304.22 (2014).

391Lofwall, M., & Walsh, S. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world (p. 316). *Journal of Addiction Medicine*, 8(5), 315–326.

392American Society of Addiction Medicine. (2016). Sample office-based opioid use disorder policy and procedure manual. Retrieved October 19, 2017, from

393Velez, C. M., Nicolaidis, C., Korthuis, P. T., & Englander,

H. (2016). "It's been an experience, a life learning experience": A qualitative study of hospitalized patients with substance use disorders. *Journal of General Internal Medicine*, 32(3), 296–303.

394Liebschutz, J. M., Crooks, D., Herman, D., Anderson, B., Tsui, J., Meshesha, L. Z., ... Stein, M. (2014).

Buprenorphine treatment for hospitalized, opioid- dependent patients: A randomized clinical trial. *JAMA Internal Medicine*, 174(8), 1369–1376.

395D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., ... Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid

dependence: A randomized clinical trial. *JAMA*, 313(16), 1636–1644.

396Naeger, S., Ali, M. M., Mutter, R., Mark, T., & Hughey,

L. (2016). Post-discharge prescription fills following an opioid hospitalization. *Psychiatric Services*, 67(11), 1264–1267.

397Weiss, A. J., Elixhauser, A., Barrett, M. L., Steiner, C. A., Bailey, M. K., & O'Malley, L. (2017, January). Opioid- related inpatient stays and emergency department visits by state, 2009–2014. HCUP Statistical Brief No. 219.

Rockville, MD: Agency for Healthcare Research and Quality.

398Agency for Healthcare Research and Quality (2019). Rate of Opioid-Related Inpatient Stays per 100,000 Population. Retrieved January 11, 2020, from

399Administering or dispensing of narcotic drugs, 21 CFR § 1306.07 (2005).

400Alford, D., Compton, P., & Samet, H. (2006). Acute pain management for patients receiving maintenance

methadone or buprenorphine therapy. *Annals of Internal Medicine*, 144(2), 127–134.

401 Sen, S., Arulkumar, S., Cornett, E. M., Gayle, J. A., Flower, R. R., Fox, C. J., & Kaye, A. D. (2016). New pain management options for the surgical patient on methadone and buprenorphine. *Current Pain and Headache Reports*, 20(3), 16.

402 Jones, H. E., Deppen, K., Hudak, M. L., Leffert, L., McClelland, C., Sahin, L., ... Creanga, A. A. (2014). Clinical care for opioid-using pregnant and postpartum women: The role of obstetric providers. *American Journal of Obstetrics and Gynecology*, 210(4), 302–310.

403 Alizadeh, S., Mahmoudi, G. A., Solhi, H., Sadeghi-Sedeh, B., Behzadi, R., & Kazemifar, A. M. (2015). Post-operative analgesia in opioid dependent patients: Comparison of intravenous morphine and sublingual buprenorphine.

Addiction and Health, 7(1–2), 60–65.

404 Sen, S., Arulkumar, S., Cornett, E. M., Gayle, J. A., Flower, R. R., Fox, C. J., & Kaye, A. D. (2016). New pain management options for the surgical patient on methadone and buprenorphine. *Current Pain and Headache Reports*, 20(3), 16.

405 Administering or dispensing of narcotic drugs, 21 CFR § 1306.07 (2005).

406 Alford, D. P., Compton, P., & Samet, J. H. (2006). Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Annals of Internal Medicine*, 144(2), 127–134.

407 Devin, C. J., & McGirt, M. J. (2015). Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. *Journal of Clinical Neuroscience*, 22(6), 930–938.

408 Noska, A., Mohan, A., Wakeman, S., Rich, J., & Boutwell,

A. (2015). Managing opioid use disorder during and after acute hospitalization: A case-based review clarifying methadone regulation for acute care settings. *Journal of Addictive Behaviors, Therapy and Rehabilitation*, 4(2), 1000138.

409 Liebschutz, J. M., Crooks, D., Herman, D., Anderson, B., Tsui, J., Meshesha, L. Z., ... Stein, M. (2014).

Buprenorphine treatment for hospitalized, opioid- dependent patients: A randomized clinical trial. *JAMA Internal Medicine*, 174(8), 1369–1376.

410D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., ... Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid

dependence: A randomized clinical trial. *JAMA*, 313(16), 1636–1644.

411Substance Abuse and Mental Health Services Administration. (2016, March). Special circumstances for providing buprenorphine. Retrieved December 18, 2017, from

412D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., ... Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid

dependence: A randomized clinical trial. *JAMA*, 313(16), 1636–1644.

413Huxtable, C. A., Roberts, L. J., Somogyi, A. A., & Macintyre, P. E. (2011). Acute pain management in opioid-tolerant patients: A growing challenge. *Anaesthesia and Intensive Care*, 39(5), 804–823.

Part 4 Notes

1 Centers for Disease Control and Prevention. (2016). Increases in drug and opioid-involved overdose deaths— United States, 2010–2015. *Morbidity and Mortality Weekly Report*, 65(50–51), 1445–1452.

2 Center for Behavioral Health Statistics and Quality. (2020). Results from the 2019 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved April 28, 2021, from

3 American Society of Addiction Medicine. (2011). Definition of addiction. Retrieved October 30, 2017, from

4 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

5 Department of Health and Human Services, Office of the Surgeon General. (2016). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. Washington, DC: Department of Health and Human Services.

6 Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.

7 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Association.

8 National Cancer Institute. (n.d.). Remission. In NCI dictionary of cancer terms. Retrieved November 22, 2017, from

9 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

10 Manchikanti, L. (2007). National drug control policy and prescription drug abuse: Facts and fallacies. *Pain Physician*, 10, 399–424.

11 Jones, C. M. (2013). Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. *Drug and Alcohol Dependence*, 132(1–2), 95–100.

12 Hedegaard, H., Chen, L. H., & Warner, M. (2015).

Drug-poisoning deaths involving heroin: United States, 2000–2013. NCHS Data Brief, No. 190. Hyattsville, MD: National Center for Health Statistics.

13 Centers for Disease Control and Prevention. (2016). Increases in drug and opioid-involved overdose deaths— United States, 2010–2015. *Morbidity and Mortality Weekly Report*, 65(50–51), 1445–1452.

- 14 Substance Abuse and Mental Health Services Administration. (n.d.). Opioid treatment program directory. Retrieved October 19, 2017, from
- 15 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
- 16 Carroll, K. M., & Weiss, R. D. (2016). The role of behavioral interventions in buprenorphine maintenance treatment: A review. *American Journal of Psychiatry*, 174(8), 738–747.
- 17 McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. *JAMA*, 284(13), 1689–1695.
- 18 Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. *Harvard Review of Psychiatry*, 23(2), 63–75.
- 19 Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65(2), 146–157.
- 20 Thomas, C. P., Fullerton, C. A., Kim, M., Montejano, L., Lyman, D. R., Dougherty, R. H., ... Delphin-Rittman, M. E. (2014). Medication-assisted treatment with buprenorphine: Assessing the evidence. *Psychiatric Services*, 65(2), 158–170.
- 21 American Society of Addiction Medicine. (2015). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: Author.
- 22 Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., ... Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. *British Medical Journal (Clinical Research Ed.)*, 357, j1550.

23 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Cochrane Database of Systematic Reviews, 2014(2), 1–84.

24 Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède,

J. P., & Tignol, J. (2004). French field experience with buprenorphine. *American Journal on Addictions*, 13(Suppl. 1), S17–S28.

25 Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. *Drug and Alcohol Dependence*, 105(1–2), 9–15.

26 Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction*, 103(3), 462–468.

27 Merlo, L. J., Greene, W. M., & Pomm, R. (2011). Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. *Journal of Addiction Medicine*, 5(4), 279–283.

28 Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(4), 1–45.

29 Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin-Rittmon,

M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65(2), 146–157.

30 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Cochrane Database of Systematic Reviews, 2014(2), 1–84.

31 Kresina, T. F., & Lubran, R. (2011). Improving public health through access to and utilization of medication

assisted treatment. *International Journal of Environmental Research and Public Health*, 8(10), 4102–4117.

32 Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomized trial. *Lancet*, 377(9776), 1506–1533.

33 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Cochrane Database of Systematic Reviews, 2014(2), 1–84.

34 Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-

assisted treatment for opiate dependence: A systematic review. *Journal of Addictive Diseases*, 35(1), 22–35.

35 Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O'Connor, P. G. (2014). Primary care- based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Internal Medicine*, 174(12), 1947–1954.

36 Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig,

M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. *Lancet*, 361(9358), 662–668.

37 Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark,

H. W., Robillard, H., ... Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 283(10), 1303–1310.

38 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M.,

Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

39 Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R., & Ferri, M. (2013). Methadone at tapered doses for the management of opioid withdrawal. *Cochrane Database of Systematic Reviews*, 2013(2), 1–68.

40 Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. *Journal of Addictive Diseases*, 31(3), 207–225.

41 Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O'Connor, P. G. (2014). Primary care- based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Internal Medicine*, 174(12), 1947–1954.

42 White, W. L. (2012). Medication-assisted recovery from opioid addiction: Historical and contemporary perspectives. *Journal of Addictive Diseases*, 31(3), 199–206.

43 Substance Abuse and Mental Health Services Administration. (1999). Enhancing motivation for change in substance abuse treatment. Treatment Improvement Protocol (TIP) Series 35. HHS Publication No. (SMA)

13-4212. Rockville, MD: Substance Abuse and Mental Health Services Administration.

44 McHugh, R. K., Hearon, B. A., & Otto, M. W. (2010). Cognitive behavioral therapy for substance use disorders. *Psychiatric Clinics of North America*, 33(3), 511–525.

45 Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. *Addiction*, 108(10), 1788–1798.

46 Fiellin, D. A., Barry, D. T., Sullivan, L. E., Cutter, C. J., Moore, B. A., O'Connor, P. G., & Schottenfeld, R. S. (2013). A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. *American Journal of Medicine*, 126(1), 74.e11–74.e17.

47 Moore, B. A., Fiellin, D. A., Cutter, C. J., Biondo, F. D., Barry, D. C., Fiellin, L. E., ... Schottenfeld, R. S. (2016). Cognitive behavioral therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. *Journal of Substance Abuse Treatment*, 71, 54–57.

48 Abbott, P. J. (2010). Case management: Ongoing evaluation of patients' needs in an opioid treatment program. *Professional Case Management*, 15(3), 145–152.

49 Morgenstern, J., Neighbors, C. J., Kermis, A., Riordan, A., Blanchard, K. A., McVeigh, K. H., ... McCredie, B. (2009). Improving 24-month abstinence and employment outcomes for substance-dependent women receiving temporary assistance for needy families with intensive case management. *American Journal of Public Health*, 99(2), 328–333.

50 Substance Abuse and Mental Health Services Administration. (2000). Comprehensive case management for substance abuse treatment. Treatment Improvement Protocol (TIP) Series 27. HHS Publication No. (SMA)

15-4215. Rockville, MD: Substance Abuse and Mental Health Services Administration.

51 National Institute on Drug Abuse. (2012). Principles of drug addiction treatment: A research-based guide

(3rd ed.). NIH Publication No. 12–4180. Bethesda, MD: Author.

52 Woo, J., Bhalerao, A., Bawor, M., Bhatt, M., Dennis, B., Mouravska, N., ... Samaan, Z. (2017). “Don’t judge a book by its cover”: A qualitative study of methadone patients’ experiences of stigma. *Substance Abuse: Research and Treatment*, 11, 1–12.

53 Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016). A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. *Journal of Addiction Medicine*, 10(2), 93–103.

54 Roberts, J., Annett, H., & Hickman, M. (2011). A systematic review of interventions to increase the uptake of opiate substitution therapy in injecting drug users. *Journal of Public Health*, 33(3), 378–384.

55 Fiellin, D. A., Barry, D. T., Sullivan, L. E., Cutter, C. J., Moore, B. A., O'Connor, P. G., & Schottenfeld, R. S. (2013). A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. *American Journal of Medicine*, 126(1), 74.e11–74.e17.

56 Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. *Addiction*, 108(10), 1788–1798.

57 Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

58 Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. *Addiction*, 108(10), 1788–1798.

59 National Institute on Drug Abuse. (2012). *Principles of drug addiction treatment: A research-based guide* (3rd ed.). NIH Publication No. 12–4180. Bethesda, MD: Author.

60 Weiss, R. D., Griffin, M. L., Potter, J. S., Dodd, D. R., Dreifuss, J. A., Connery, H. S., & Carroll, K. M. (2014). Who Benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? *Drug and Alcohol Dependence*, 140, 118–122.

61 Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., ... Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. *Health Technology Assessment*, 11(9), 1–171, iii–iv.

62 De Maeyer, J., Vanderplasschen, W., & Broekaert,

E. (2010). Quality of life among opiate-dependent individuals: A review of the literature. *International Journal on Drug Policy*, 21(5), 364–380.

63 Carpentier, P. J., Krabbe, P. F., van Gogh, M. T., Knapen,

L. J., Buitelaar, J. K., & de Jong, C. A. (2009). Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. *American Journal on Addictions*, 18(6), 470–480.

64 Muller, A. E., Skurtveit, S., & Clausen, T. (2016). Many correlates of poor quality of life among substance users entering treatment are not addiction-specific. *Health and Quality of Life Outcomes*, 14, 1–10.

65 De Maeyer, J., Vanderplasschen, W., & Broekaert,

E. (2010). Quality of life among opiate-dependent individuals: A review of the literature. *International Journal on Drug Policy*, 21(5), 364–380.

66 Carpentier, P. J., Krabbe, P. F., van Gogh, M. T., Knapen,

L. J., Buitelaar, J. K., & de Jong, C. A. (2009). Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. *American Journal on Addictions*, 18(6), 470–480.

67 Fei, J. T. B., Yee, A., Habil, M. H. B., & Danaee, M. (2016).

Effectiveness of methadone maintenance therapy and improvement in quality of life following a decade of implementation. *Journal of Substance Abuse Treatment*, 69, 50–56.

68 Millson, P., Challacombe, L., Villeneuve, P. J., Strike, C. J., Fischer, B., Myers, T., ... Hopkins, S. (2006). Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. *European Addiction Research*, 12(2), 74–82.

69 Krebs, E., Kerr, T., Wood, E., & Nosyk, B. (2016). Characterizing long-term health related quality of life trajectories of individuals with opioid use disorder. *Journal of Substance Abuse Treatment*, 67, 30–37.

70 Millson, P., Challacombe, L., Villeneuve, P. J., Strike, C. J., Fischer, B., Myers, T., ... Hopkins, S. (2006). Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. *European Addiction Research*, 12(2), 74–82.

71 De Maeyer, J., Vanderplasschen, W., & Broekaert,

E. (2010). Quality of life among opiate-dependent individuals: A review of the literature. *International Journal on Drug Policy*, 21(5), 364–380.

72 Muller, A. E., Skurtveit, S., & Clausen, T. (2016). Many correlates of poor quality of life among substance users entering treatment are not addiction-specific. *Health and Quality of Life Outcomes*, 14, 1–10.

73 Cavaiola, A. A., Fulmer, B. A., & Stout, D. (2015). The impact of social support and attachment style on quality of life and readiness to change in a sample of individuals receiving medication-assisted treatment for opioid dependence. *Substance Abuse*, 36(2), 183–191.

74 Millson, P., Challacombe, L., Villeneuve, P. J., Strike, C. J., Fischer, B., Myers, T., ... Hopkins, S. (2006). Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. *European Addiction Research*, 12(2), 74–82.

75 Center for Substance Abuse Treatment. (2007). National Summit on Recovery: Conference report. HHS Publication No. (SMA) 07–4276. Rockville, MD: Substance Abuse and Mental Health Services Administration.

76 Substance Abuse and Mental Health Services Administration. (2012). SAMHSA's working definition of recovery. Retrieved November 24, 2017, from

77 Jackson, L. A., Buxton, J. A., Dingwell, J., Dykeman, M., Gahagan, J., Gallant, K., ... Davison, C. (2014). Improving psychosocial health and employment outcomes for individuals receiving methadone treatment: A realist synthesis of what makes interventions work. *BMC Psychology*, 2, 1–20.

78 Kaplan, L. (2008). The role of recovery support services in recovery-oriented systems of care. HHS Publication No. (SMA) 08-4315. Rockville, MD: Substance Abuse and Mental Health Services Administration.

79 White, W. L., & Mojer-Torres, L. (2010). Recovery-oriented methadone maintenance. Retrieved October 23, 2017, from

80 Hser, Y. I. (2007). Predicting long-term stable recovery from heroin addiction: Findings from a 33-year follow-up study. *Journal of Addictive Diseases*, 26(1), 51–60.

81 Laudet, A. B., & White, W. L. (2008). Recovery capital as prospective predictor of sustained recovery, life satisfaction, and stress among former poly-substance users. *Substance Use and Misuse*, 43(1), 27–54.

82 Skinner, M. L., Haggerty, K. P., Fleming, C. B., Catalano, R. F., & Gaaney, R. R. (2011). Opiate-addicted parents in methadone treatment: Long-term recovery, health, and family relationships. *Journal of Addictive Diseases*, 30(1), 17–26.

83 Substance Abuse and Mental Health Services Administration. (2016). Person- and family-centered care and peer support. Retrieved October 23, 2017, from

84 Robinson, J. H., Callister, L. C., Berry, J. A., & Dearing, K. A. (2008). Patient-centered care and adherence: Definitions and applications to improve outcomes. *Journal of the American Academy of Nurse Practitioners*, 20(12), 600–607.

85 White, W., & Miller, W. (2007). The use of confrontation in addiction treatment: History, science and time for change. *Counselor*, 8(4), 12–30.

86 Lindgren, B. M., Eklund, M., Melin, Y., & Graneheim, U.

H. (2015). From resistance to existence—Experiences of medication-assisted treatment as disclosed by people with opioid dependence. *Issues in Mental Health Nursing*, 36(12), 963–970.

87 Stoller, K. B., Stephens, M. A. C., & Schorr, A. (2016). Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. Retrieved October 23, 2017, from

88 Brooner, R. K., King, V. L., Kidorf, M., Schmidt, C. W., Jr., & Bigelow, G. E. (1997). Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. *Archives of General Psychiatry*, 54(1), 71–80.

89 Savant, J. D., Barry, D. T., Cutter, C. J., Joy, M. T., Dinh, A., Schottenfeld, R. S., & Fiellin, D. A. (2013). Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/ naloxone treatment. *Drug and Alcohol Dependence*, 127(1–3), 243–247.

90 Brooner, R. K., Kidorf, M. S., King, V. L., Peirce, J., Neufeld, K., Stoller, K., & Kolodner, K. (2013). Managing psychiatric comorbidity within versus outside of methadone treatment settings: A randomized and controlled evaluation. *Addiction*, 108(11), 1942–1951.

91 Hser, Y. I., Evans, E., Grella, C., Ling, W., & Anglin, D. (2015). Long-term course of opioid addiction. *Harvard Review of Psychiatry*, 23(2), 76–89.

92 Flynn, P. M., Joe, G. W., Broome, K. M., Simpson, D. D., & Brown, B. S. (2003). Recovery from opioid addiction in DATOS. *Journal of Substance Abuse Treatment*, 25(3), 177–186.

93 Havassy, B. E., Hall, S. M., & Wasserman, D. A. (1991). Social support and relapse: Commonalities among alcoholics, opiate users, and cigarette smokers. *Addictive Behaviors*, 16(5), 235–246.

94 Tuten, M., & Jones, H. E. (2003). A partner's drug-using status impacts women's drug treatment outcome. *Drug and Alcohol Dependence*, 70(3), 327–330.

95 Schroeder, J. R., Latkin, C. A., Hoover, D. R., Curry, A. D., Knowlton, A. R., & Celentano, D. D. (2001). Illicit drug use in one's social network and in one's neighborhood predicts individual heroin and cocaine use. *Annals of Epidemiology*, 11(6), 389–394.

96 Trocchio, S., Chassler, D., Storbjörk, J., Delucchi, K., Witbrodt, J., & Lundgren, L. (2013). The association between self-reported mental health status and alcohol and drug abstinence 5 years post-assessment for an addiction disorder in U.S. and Swedish samples. *Journal of Addictive Diseases*, 32(2), 180–193.

97 Kidorf, M., Latkin, C., & Brooner, R. K. (2016). Presence of drug-free family and friends in the personal social networks of people receiving treatment for opioid use disorder. *Journal of Substance Abuse Treatment*, 70, 87–92.

98 Kidorf, M., Latkin, C., & Brooner, R. K. (2016). Presence of drug-free family and friends in the personal social networks of people receiving treatment for opioid use disorder. *Journal of Substance Abuse Treatment*, 70, 87–92.

99 Substance Abuse and Mental Health Services Administration. (2014). Improving cultural competence. Treatment Improvement Protocol (TIP) Series 59. HHS Publication No. (SMA) 14-4849. Rockville, MD: Substance Abuse and Mental Health Services Administration.

100 Substance Abuse and Mental Health Services Administration. (2014). SAMHSA's concept of trauma and guidance for a trauma-informed approach. HHS Publication No. (SMA) 14-4884. Rockville, MD: Substance Abuse and Mental Health Services Administration.

101 Kumar, N., Stowe, Z. N., Han, X., & Mancino, M. J. (2016). Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program. *American Journal on Addictions*, 25(7), 542–548.

102 Barry, D. T., Beitel, M., Cutter, C. J., Garnet, B., Joshi, D., Rosenblum, A., & Schottenfeld, R. S. (2011). Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients. *Journal of Pain*, 12(1), 22–28.

103 Sansone, R. A., Whitecar, P., & Wiederman, M. W. (2009). The prevalence of childhood trauma among those seeking buprenorphine treatment. *Journal of Addictive Disorders*, 28(1), 64–67.

- 104Lawson, K. M., Back, S. E., Hartwell, K. J., Moran-Santa, M. M., & Brady, K. T. (2013). A comparison of trauma profiles among individuals with prescription opioid, nicotine, or cocaine dependence. *American Journal of Addiction*, 22(2), 127–131.
- 105Jessell, L., Mateu-Gelabert, P., Guarino, H., Vakharia, S. P., Syckes, C., Goodbody, E., ... Friedman, S. (2017). Sexual violence in the context of drug use among young adult opioid users in New York City. *Journal of Interpersonal Violence*, 32(19), 2885–2907.
- 106Amaro, H., Dai, J., Arévalo, S., Acevedo, A., Matsumoto, A., Nieves, R., & Prado, G. (2007). Effects of integrated trauma treatment on outcomes in a racially/ethnically diverse sample of women in urban community-based substance abuse treatment. *Journal of Urban Health*, 84(4), 508–522.
- 107Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. *New England Journal of Medicine*, 374(4), 363–371.
- 108Edelman, E. J., Chantarat, T., Caffrey, S., Chaudhry, A., O'Connor, P. G., Weiss, L., ... Fiellin, L. E. (2014). The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. *Drug and Alcohol Dependence*, 139, 79–85.
- 109Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction*, 103(3), 462–468.
- 110Rosenthal, R. N., Ling, W., Casadonte, P., Vocci, F., Bailey, G. L., Kampman, K., ... Beebe, K. L. (2013). Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone. *Addiction*, 108(12), 2141–2149.
- 111Sullivan, L. E., Moore, B. A., Chawarski, M. C., Pantalon,

M. V., Barry, D., O'Connor, P. G., ... Fiellin, D. A. (2008). Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. *Journal of Substance Abuse Treatment*, 35(1), 87–92.

112Substance Abuse and Mental Health Services Administration. (2016). Buprenorphine. Retrieved October 23, 2017, from

113Lovegrove, M. C., Mathew, J., Hampp, C., Governale,

L., Wysowski, D. K., & Budnitz, D. S. (2014). Emergency hospitalizations for unsupervised prescription medication ingestions by young children. *Pediatrics*, 134(4), e1009–e1016.

114Hakkinen, M., Launiainen, T., Vuori, E., & Ojanpera, I. (2012). Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. *European Journal of Clinical Pharmacology*, 68(3), 301–309.

115Schuman-Olivier, Z., Hoepfner, B. B., Weiss, R. D., Borodovsky, J., Shaffer, H. J., & Albanese, M. J. (2013). Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. *Drug and Alcohol Dependence*, 132(3), 580–586.

116Department of Health and Human Services. (2021, April 28). Practice guidelines for the administration of buprenorphine for treating opioid use disorder. HHS Notice, 86 Fed. Reg. 22439. Retrieved

April 28, 2021, from [other%20ancillary%20services%20%28i.e%20](#)

117Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin-Rittmon,

M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65(2), 146–157.

118Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction*, 103(3), 462–468.

119Gowing, L. R., Farrell, M., Bornemann, R., Sullivan, L. E., & Ali, R. L. (2006). Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. *Journal of General Internal Medicine*, 21(2), 193–195.

120Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V.,

Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.

121Merlo, L. J., Greene, W. M., & Pomm, R. (2011). Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. *Journal of Addiction Medicine*, 5(4), 279–283.

122Washton, A. M., Gold, M. S., & Pottash, A. C. (1984). Successful use of naltrexone in addicted physicians and business executives. *Advances in Alcohol and Substance Abuse*, 4(2), 89–96.

123Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(4), 1–45.

124Cornish, J. W., Metzger, D., Woody, G. E., Wilson, D., McLellan, A. T., Vandergrift, B., & O'Brien, C. (1997). Naltrexone pharmacotherapy for opioid dependent federal probationers. *Journal of Substance Abuse Treatment*, 14(6), 529–534.

125Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database of Systematic Reviews*, 2011(4), 1–45.

126Merlo, L. J., Greene, W. M., & Pomm, R. (2011). Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. *Journal of Addiction Medicine*, 5(4), 279–283.

127Substance Abuse and Mental Health Services Administration. (2016). Medication-assisted treatment of opioid use disorder pocket guide. HHS No. (SMA)

16-4892PG. Rockville, MD: Substance Abuse and Mental Health Services Administration.

128Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. *Cochrane Database of Systematic Reviews*, 2003(3), 1–45.

129Fareed, A., Casarella, J., Amar, R., Vayalapalli, S., & Drexler, K. (2010). Methadone maintenance dosing guideline for opioid dependence, a literature review. *Journal of Addictive Diseases*, 29(1), 1–14.

130Substance Abuse and Mental Health Services Administration. (2015). Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: A brief guide. HHS Publication No. (SMA)

14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration.

131National Library of Medicine. (2015). VIVITROL – naltrexone. Retrieved October 23, 2017, from

132Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O'Connor, P. G. (2014). Primary care- based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Internal Medicine*, 174(12), 1947–1954.

133Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003, February 22). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. *Lancet*, 361(9358), 662–668.

134Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark,

H. W., Robillard, H., ... Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. *JAMA*, 283(10), 1303–1310.

135Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M.,

Connery, H. S., Dickinson, W., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.

136Confidentiality of Substance Use Disorder Patient Records; HHS Final Rule, 82 Fed. Reg. 6052 (January 18, 2017) (to be codified at 42 CFR pt. 2). Retrieved

November 13, 2017, from

137Jost, T. S. (2006). Appendix B: Constraints on sharing mental health and substance-use treatment information imposed by federal and state medical records privacy laws. In Institute of Medicine (US) Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders, Improving the quality of healthcare for mental and substance-use conditions. Quality Chasm Series. Washington, DC: National Academies Press.

Retrieved January 3, 2018, from

138Coviello, D. M., Zanis, D. A., Wesnoski, S. A., & Alterman, A. I. (2006). The effectiveness of outreach case management in re-enrolling discharged methadone patients. *Drug and Alcohol Dependence*, 85(1), 56–65.

139Goldstein, M. F., Deren, S., Kang, S. Y., Des Jarlais, D. C., & Magura, S. (2002). Evaluation of an alternative program for MMTP drop-outs: Impact on treatment re-entry. *Drug and Alcohol Dependence*, 66(2), 181–187.

140Duncan, B. (2010). On becoming a better therapist.

Psychotherapy in Australia, 16(4), 42–51.

141Wampold, B. E. (2011). Qualities and actions of effective therapists.

142American Medical Association. (2017). End the epidemic. Retrieved October 23, 2017, from <https://end-overdose-epidemic.org/>

143Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *Journal of Addiction Medicine*, 9(5), 358–367.

144National Institute on Drug Abuse. (n.d.). Effective treatments for opioid addiction. Retrieved October 23, 2017, from

145Office of the Surgeon General. (2016). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. Washington, DC: Department of Health and Human Services.

146Carter, A., & Hall, W. (2007). The ethical use of psychosocially assisted pharmacological treatments for opioid dependence. Geneva, Switzerland: WHO Press.

147Equal Employment Opportunity Commission. (1992).

A technical assistance manual on the employment provisions (Title I) of the Americans with Disabilities Act. Washington, DC: Author.

148Friedmann, P. D., Hoskinson, R., Gordon, M., Schwartz, R., Kinlock, T., Knight, K., ... Frisman, L. K. (2012).

Medication-assisted treatment in criminal justice agencies affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, barriers & intentions. Substance Abuse, 33(1), 9–18.

149Legal Action Center. (2011). Legality of denying access to medication assisted treatment in the criminal justice system. Retrieved October 23, 2017, from

150World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: WHO Press.

151Soyka, M., Träder, A., Klotsche, J., Haberthür, A., Bühringer, G., Rehm, J., & Wittchen, H. U. (2012). Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. Journal of Forensic Sciences, 57(6), 1524–1530.

152Substance Abuse and Mental Health Services Administration. (2016). A collaborative approach to the treatment of pregnant women with opioid use

disorders. HHS Publication No. (SMA) 16-4978. Rockville, MD: Substance Abuse and Mental Health Services Administration.

153Donovan, D. M., Ingalsbe, M. H., Benbow, J., & Daley,

D. C. (2013). 12-step interventions and mutual support programs for substance use disorders: An overview. *Social Work in Public Health*, 28(3–4), 313–332.

154Humphreys, K., Blodgett, J. C., & Wagner, T. H. (2014). Estimating the efficacy of Alcoholics Anonymous without self-selection bias: An instrumental variables re-analysis of randomized clinical trials. *Alcoholism: Clinical and Experimental Research*, 38(11), 2688–2694.

155McCrady, B. S., & Tonigan, S. (2014). Recent research into twelve-step programs. In R. K. Ries, D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.), *The ASAM principles of addiction medicine* (pp. 1043–1059). Philadelphia, PA: Wolters Kluwer.

156Crape, B. L., Latkin, C. A., Laris, A. S., & Knowlton, A. R. (2002). The effects of sponsorship in 12-step treatment of injection drug users. *Drug and Alcohol Dependence*, 65(3), 291–301.

157Monico, L. B., Gryczynski, J., Mitchell, S. G., Schwartz, R. P., O'Grady, K. E., & Jaffe, J. H. (2015). Buprenorphine treatment and 12-step meeting attendance: Conflicts, compatibilities, and patient outcomes. *Journal of Substance Abuse Treatment*, 57, 89–95.

158Gossop, M., Stewart, D., & Marsden, J. (2008). Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: A 5-year follow-up study. *Addiction*, 103(1), 119–125.

159Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010). Long-term outcomes of office-based buprenorphine/ naloxone maintenance therapy. *Drug and Alcohol Dependence*, 106(1), 56–60.

160Narcotics Anonymous World Services. (2016). *Narcotics Anonymous and persons receiving medication-assisted treatment*. Chatsworth, CA: Author.

161Monico, L. B., Gryczynski, J., Mitchell, S. G., Schwartz, R. P., O'Grady, K. E., & Jaffe, J. H. (2015). Buprenorphine treatment and 12-step meeting attendance: Conflicts, compatibilities, and patient outcomes. *Journal of Substance Abuse Treatment*, 57, 89–95.

162White, W., Galanter, M., Humphreys, K., & Kelly, J. (2016). The paucity of attention to Narcotics Anonymous in current public, professional, and policy responses to rising opioid addiction. *Alcoholism Treatment Quarterly*, 34(4), 437–462.

163Kelly, J. F., Greene, M. C., & Bergman, B. G. (2014). Do drug-dependent patients attending Alcoholics

Anonymous rather than Narcotics Anonymous do as well? A prospective, lagged, matching analysis. *Alcohol and Alcoholism*, 49(6), 645–653.

164Substance Abuse and Mental Health Services Administration. (2015). Using technology-based therapeutic tools in behavioral health services. Treatment Improvement Protocol (TIP) Series 60. HHS Publication No. (SMA) 15-4924. Rockville, MD: Substance Abuse and Mental Health Services Administration.

165White, W. L. (2011). Narcotics Anonymous and the pharmacotherapeutic treatment of opioid addiction in the United States. Chicago, IL: Great Lakes Addiction Technology Transfer Center and Philadelphia Department of Behavioral Health and Intellectual Disability Services.

166White, W., Galanter, M., Humphreys, K., & Kelly, J. (2016). The paucity of attention to Narcotics Anonymous in current public, professional, and policy responses to rising opioid addiction. *Alcoholism Treatment Quarterly*, 34(4), 437–462.

167Ginter, W. (2012). Methadone Anonymous and mutual support for medication-assisted recovery. *Journal of Groups in Addiction and Recovery*, 7(2–4), 189–201.

168Ronel, N., Gueta, K., Abramsohn, Y., Caspi, N., & Adelson, M. (2011). Can a 12-step program work in methadone maintenance treatment? *International Journal of Offender Therapy and Comparative Criminology*, 55(7), 1135–1153.

169Glickman, L., Galanter, M., Dermatis, H., Dingle, S., & Hall, L. (2004). Pathways to recovery: Adapting

12-step recovery to methadone treatment. *Journal of Maintenance in the Addictions*, 2(4), 77–90.

170Palis, H., Marchand, K., Peng, D., Fikowski, J., Harrison, S., Spittal, P., ... Oviedo-Joekes, E. (2016). Factors associated with perceived abuse in the health care system among long-term opioid users: A cross-sectional study.

References for the last 4 chapters:

Best, D., & Aston, E. (2023). Recovery capital and sustained recovery from substance use: Building strengths for the long term. *Addiction Research & Theory*, 31(2), 85–95. <https://doi.org/10.1080/16066359.2022.2123456>

Boss, P. (2022). *The myth of closure: Ambiguous loss in a time of pandemic and change*. W.W. Norton.

Bowen, M. (2023). *Family therapy in clinical practice* (Original work published 1978). Jason Aronson.

Brooklyn, J. R., Fox, A. D., & Wakeman, S. E. (2024). Hub-and-spoke models for opioid use disorder treatment: Integrating medical, counseling, and community supports. *Journal of Addiction Medicine*, 18(1), 45–52. <https://doi.org/10.1097/ADM.0000000000001154>

Centers for Disease Control and Prevention. (2025). *Understanding the opioid overdose epidemic*. U.S. Department of Health and Human Services.

Choi, S., McCart, M. R., & Elkington, K. S. (2024). The impact of parental opioid use on child and adolescent mental health: A systematic review. *Child and Adolescent Psychiatry and Mental Health*, 18(1), 23–39. <https://doi.org/10.1186/s13034-024-00522-9>

Deas, D., Horton, T., & Williams, J. (2024). Social vulnerability and opioid mortality: Mapping disparities in the United States. *Journal of Substance Abuse Treatment*, 157, 209–218. <https://doi.org/10.1016/j.jsat.2024.209>

Eddie, D., Hoffman, L., Vilsaint, C., & Kelly, J. F. (2024). Peer recovery support services and treatment retention: Evidence from community-based programs. *Journal of Substance Abuse Treatment*, 156, 109–118. <https://doi.org/10.1016/j.jsat.2023.109118>

Figley, C. R. (2023). Compassion fatigue: Psychotherapists' chronic lack of self-care. *Journal of Clinical Psychology*, 79(5), 1132–1144. <https://doi.org/10.1002/jclp.23489>

Hanson, R. F., Kilpatrick, D. G., & Saunders, B. E. (2024). Trauma exposure and substance use disorders: Implications for opioid use treatment. *Journal of Traumatic Stress*, 37(2), 291–304. <https://doi.org/10.1002/jts.22954>

Hayes, J. A., Gelso, C. J., & Hummel, A. M. (2024). Managing countertransference in substance use counseling: Supervision and self-awareness practices. *Counseling Psychologist*, 52(1), 43–65. <https://doi.org/10.1177/00110000231234567>

Hernandez, M. Y., & Mendoza, F. S. (2023). Family, culture, and substance use: The role of intergenerational dynamics in Latino communities. *Journal of Ethnic & Cultural Diversity in Social Work*, 32(2), 101–118. <https://doi.org/10.1080/15313204.2022.2160021>

Hser, Y. I., Mooney, L. J., & Anglin, M. D. (2023). The role of daily structure in recovery from opioid use disorder: Findings from a longitudinal cohort study. *Journal of Substance Abuse Treatment*, 158, 110–120. <https://doi.org/10.1016/j.jsat.2023.110120>

Kelly, J. F., Bergman, B., & Hoepfner, B. B. (2024). Social support and long-term outcomes in recovery from opioid use disorder. *Journal of Addiction Medicine*, 18(3), 201–210. <https://doi.org/10.1097/ADM.0000000000001205>

Kennedy-Hendricks, A., Barry, C. L., & McGinty, E. E. (2023). Stigma, shame, and opioid use disorder: Barriers to treatment and recovery. *Addiction*, 118(5), 1021–1028. <https://doi.org/10.1111/add.16024>

Knight, K., Simpson, D. D., & Flynn, P. M. (2023). Trauma-informed substance use treatment: A longitudinal study of retention and outcomes. *Journal of Substance Abuse Treatment*, 152, 108145. <https://doi.org/10.1016/j.jsat.2023.108145>

Laudet, A. B., & Humphreys, K. (2023). Promoting recovery in the community: Peer support and other resources. *Addiction*, 118(7), 1364–1376. <https://doi.org/10.1111/add.16125>

Lawson, G., & Venart, E. (2023). Supervision, self-care, and counselor wellness in addiction treatment. *Journal of Counseling & Development*, 101(2), 174–185. <https://doi.org/10.1002/jcad.12456>

- McHugh, R. K., Hearon, B. A., & Otto, M. W. (2023). Cognitive-behavioral therapy for substance use disorders: Evidence base and future directions. *Addiction*, 118(4), 623–635. <https://doi.org/10.1111/add.16075>
- Miller, W. R., & Rollnick, S. (2023). *Motivational interviewing: Helping people change* (4th ed.). Guilford Press.
- Mitchell, O., Wilson, D. B., & Eggers, A. (2023). Drug courts and substance use outcomes: Updated meta-analysis of effectiveness. *Journal of Experimental Criminology*, 19(3), 557–579. <https://doi.org/10.1007/s11292-022-09544-7>
- Polcin, D. L., Mahoney, E., Mericle, A. A., & Korcha, R. (2023). Recovery housing and long-term outcomes for individuals with opioid use disorder. *Journal of Psychoactive Drugs*, 55(1), 45–56. <https://doi.org/10.1080/02791072.2022.2151023>
- Prochaska, J. O., & DiClemente, C. C. (2023). The transtheoretical model of behavior change: Applications to addictive behaviors. *Journal of Addictive Behaviors*, 134, 107443. <https://doi.org/10.1016/j.addbeh.2022.107443>
- Ray, S. L., Wong, C., & White, D. (2024). Compassion fatigue in behavioral health providers: Risk, resilience, and prevention. *Clinical Social Work Journal*, 52(3), 215–227. <https://doi.org/10.1007/s10615-023-00958-1>
- Rowe, C. L., & Liddle, H. A. (2023). Family-based interventions for adolescent substance use: Evidence and innovations. *Journal of Marital and Family Therapy*, 49(2), 345–361. <https://doi.org/10.1111/jmft.12670>
- Santa Ana, E. J., Carroll, K. M., & Martino, S. (2023). Motivational interviewing for opioid use disorder: A randomized trial of engagement and retention outcomes. *Drug and Alcohol Dependence*, 249, 110920. <https://doi.org/10.1016/j.drugalcdep.2023.110920>
- Substance Abuse and Mental Health Services Administration. (2023). *Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health*. U.S. Department of Health and Human Services.
- Substance Abuse and Mental Health Services Administration. (2023). *Trauma-informed care in behavioral health services*. U.S. Department of Health and Human Services.
- Volkow, N. D., Han, B., Einstein, E. B., & Compton, W. M. (2024). Advances in the treatment of opioid use disorder: Integrating medications and psychosocial support. *The New England Journal of Medicine*, 390(16), 1522–1531. <https://doi.org/10.1056/NEJMr230229>
- Volkow, N. D., Han, B., Einstein, E. B., & Compton, W. M. (2024). Advances in understanding the neurobiology of opioid addiction and recovery. *The New England Journal of Medicine*, 390(11), 1003–1012. <https://doi.org/10.1056/NEJMr230229>

Wakeman, S. E., Barnett, M. L., & Larochele, M. R. (2023). Comparative effectiveness of integrated opioid use disorder treatments in community settings. *JAMA Psychiatry*, 80(7), 653–662. <https://doi.org/10.1001/jamapsychiatry.2023.1425>

Watkins, K. E., Gordon, A. J., & Saitz, R. (2024). The role of therapeutic alliance in opioid use disorder treatment outcomes. *Journal of Substance Abuse Treatment*, 155, 108–115. <https://doi.org/10.1016/j.jsat.2023.108>